Combination therapy

Combining 4-L-[¹³¹I]iodo-phenylalanine with chemotherapy and radiotherapy provides an improved treatment regimen for gliomas, enhancing survival and reducing tumor size, addressing the limitations of current glioblastoma therapies.

WO2026236807A1PCT designated stage Publication Date: 2026-11-19TELIX PHARM (INNOVATIONS) PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2026/050491
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-07-02
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for gliomas, particularly glioblastoma, are ineffective in prolonging survival and managing recurrence, with standard therapies offering a 5-year survival rate of only 6.8% and limited efficacy against DNA-repairing cancer cells.

Method used

Administering a therapeutically effective amount of 4-L-[¹³¹I]iodo-phenylalanine, optionally combined with nitrosourea chemotherapy, external beam radiotherapy, and/or Temozolomide chemotherapy, to treat gliomas.

Benefits of technology

Improves treatment outcomes for gliomas, including glioblastoma, by increasing progression-free survival and overall survival, reducing tumor size, and enhancing quality of life without significant adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure AU2026050491_19112026_PF_FP_ABST
    Figure AU2026050491_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with one or more of a nitrosourea chemotherapy, external beam radiotherapy, and Temozolomide chemotherapy, to a patient in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

COMBINATION THERAPYFIELDThe present disclosure is directed to methods of treating gliomas. The methods comprise administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), to a patient in need thereof. The methods may also comprise administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, external beam radiotherapy, and / or Temozolomide chemotherapy.BACKGROUNDGliomas account for about 80% of all malignant brain and central nervous system tumors. Malignant gliomas include glioblastomas, astrocytomas, oligodendrogliomas, and ependymomas, are a family of cancerous tumours that originate in the glial cells of the brain or the spine.Glioblastoma, also known as glioblastoma multiforme, accounts for 60% to 70% of malignant gliomas and is the most aggressive type of glioma, associated with substantial morbidity and mortality. It occurs mostly in adults (median age at diagnosis: 64 years) and its incidence is estimated to be 3.22 / 100,000 persons in the United States. Initially, the symptoms of glioblastoma are non-specific, though they often can progress to include headaches, nausea, personality changes, and even unconsciousness. While the cause of glioblastoma remains largely unknown, known risk factors include genetic disorders (e.g., Li-Fraumeni syndrome, neurofibromatosis) and previous radiation therapy. Glioblastomas are typically diagnosed through a combinatorial approach of computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, and tissue biopsy.First line treatment of glioblastoma involves surgery, in which maximal tumour resection is undertaken. Surgery is typically followed by a combined treatment regimen of chemotherapy and radiotherapy. To this extent, Temozolomide, sold under the trade names Temodar®, Temodal®, and Temcad® amongst others, is a first-line therapeutic agent in the chemotherapy of glioblastoma. Temozolomide exerts its chemotherapeutic effect by alkylating / methylating DNA of cancerous cells, thereby triggering their death. However, some cancerous cells are able to repair the damaged DNA, and are therefore able to overcome Temozolomide treatment, rendering Temozolomide only limitedly effective. As a consequence, vigorous radiotherapy (e.g., external beam radiation) is used in combination with Temozolomide chemotherapy for maximal therapeutic effect.However, even with a combined treatment approach of Temozolomide chemotherapy and external beam radiotherapy, the prognosis of a patient having been diagnosed with glioblastoma remains poor. The typical length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 7% of people surviving for longer than five years.Indeed, despite aggressive surgery and current standard of care radiotherapy and chemotherapy regimens, the rate of glioblastoma recurrence is very high. Standard of care treatments for recurrent or progressive glioblastoma (‘second line’ treatments) are not well defined, and treatment is typically selected based on prior therapy, age, Karnofsky Performance Score, 0(6)-methylguanine-DNA methyl-transferase promoter methylation status, and patterns of disease progression. Despite ongoing efforts to improve second line treatments, the 5-year relative overall survival rate remains very low at 6.8%.Accordingly, there remains a need for improved therapies and / or treatment regimens for the treatment of gliomas.SUMMARYThe present inventors have surprisingly discovered an improved therapy and / or treatment regimen for the treatment of glioma.In one aspect, the present disclosure provides methods of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), to a patient in need thereof.In another aspect, the present disclosure also provides methods of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, to a patient in need thereof.In some embodiments, the glioma is a glioblastoma. In some embodiments, the glioma is a high-grade glioma. In some embodiments, the glioma is a recurrent high-grade glioma.In another aspect, the present disclosure also provides methods of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy, to a patient in need thereof.In another aspect, the present disclosure also provides methods of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, to a patient in need thereof.In another aspect, the present disclosure also provides methods of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy, and external beam radiotherapy, to a patient in need thereof.In some embodiments, the compound of Formula I is:OFormula I;wherein X is selected from the group consisting of -O-, -N(H)-, -N[(C3-C6)cycloalkyl]-, and -N[(Ci-C6)alkyl]-; R1and R2are each independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C7)cycloalkyl, or X and R1together form a (C3-C5)heterocycle; R3is selected from the group consisting of -I,

[123] I,

[124] I,

[125] I, and

[131] I; R4is selected from the group consisting of -H, -F, or

[18] F; R5is selected from the group consisting of -PG, -(Ci-C6)alkyl, and -(C3-C6)cycloalkyl; R6and R7are each independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C6)cycloalkyl, or R6and R7together form a (C3-C5)heterocycle; wherein, if present, each PG is independently a protecting group; m is 0, 1, 2, or 3; n is 0, 1, or 2; or a pharmaceutically acceptable salt or stereoisomer thereof.Any embodiment herein shall be taken to apply mutatis mutandis to any other embodiment unless specifically stated otherwise. For instance, as the skilled person would understand, details of the amounts of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to be administered in the course of the methods described herein may be applicable to all aspects and embodiments of the present disclosure. Equally, any particulars of the administration of the disclosed chemotherapy agents or external beam radiotherapy that may be administered in combination with a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), such as the associated timing and doses, may be applicable to all aspects and embodiments described herein. Similarly, all comments on the patient population, types of glioma to be treated, and / or maintenance chemotherapy, are to be taken as applicable to all aspects and embodiments described herein.The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally -equivalentproducts, compositions and methods are clearly within the scope of the invention, as described herein.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a diagram showing the overview of the clinical trial described in Example 1. MTD: Maximum Tolerated Dose; mOS: median overall survival.FIG. 2 is a diagram depicting the BOIN Study Design for the clinical trial described in Example 1. DLT: dose limiting toxicity; MTD: maximum tolerated dose.FIG. 3 is a diagram depicting the BOIN Flow Chart for the clinical trial described in Example 1.FIG. 4 is a diagram depicting the BOIN Flow Chart for the clinical trial described in Example 3.DETAILED DESCRIPTIONGeneral Techniques and DefinitionsUnless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, medicinal chemistry and the like). As used herein, the term “and / or”, e.g., “X and / or Y” shall be understood to mean either "X and Y" or "X or Y" and shall be taken to provide explicit support for both meanings or for either meaning.As used herein, the term about, unless stated to the contrary, refers to + / - 20%, more preferably + / - 10%, of the designated value.As used herein, singular forms “a”, “an” and “the” include plural aspects, unless the context clearly indicates otherwise.Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.Throughout this specification, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.As used herein, the terms “patient” or “subject” refer to any organism susceptible to a cancer, particularly a glioblastoma. For example, the subject can be a mammal, primate, livestock (e.g., sheep, cow, horse, pig), companion animal (e.g., dog, cat), or laboratory animal (e.g.,mouse, rabbit, rat, guinea pig, hamster). In one example, the subject is a mammal. In one embodiment, the subject is a human. In one embodiment, the disease or condition is a glioblastoma.As used herein, the term “treating” includes alleviation of the symptoms associated with a specific disorder or condition and reducing and / or eliminating said symptoms. For example, as used herein, the term “treating a cancer” refers to alleviating the symptoms associated with a cancer and reducing and / or eliminating the symptoms associated with a cancer. In one example, the term “treating” includes alleviation of the symptoms associated with a glioblastoma. For example, as used herein, the term “treating a glioblastoma” refers to alleviating the symptoms associated with a glioblastoma and reducing and / or eliminating the symptoms associated with a glioblastoma. In one example, the term “treating cancer” refers to an increase in progression-free survival (PFS). As used herein, the term “progression-free survival” refers to the length of time during and after the treatment of a cancer that a patient lives with the disease, i.e., glioblastoma, but does not have a recurrence or increase in symptoms of the disease. In one embodiment, the term “preventing glioblastoma” refers to slowing or halting the progression of the glioblastoma. In one example, “preventing glioblastoma” refers to slowing or halting the glioblastoma increasing in size / volume. In one example, “preventing glioblastoma” refers to slowing or preventing metastasis.As used herein, the term “therapeutically effective amount” refers to a therapeutic agent and / or treatment approach, or a combination of therapeutic agents and / or treatment approaches, being administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated. The result can be the reduction and / or alleviation of the signs, symptoms, or causes of a disease or condition, or any other desired alteration of a biological system. In one embodiment, the term “therapeutically effective amount” refers to a therapeutic agent being administered in an amount sufficient to result in a reduction of one or more symptoms associated with a cancer (e.g., glioblastoma). In the example of a cancerous tumour, the result may be a reduction in tumour size. In one example, the term “therapeutically effective amount” refers to a therapeutic agent being administered in an amount sufficient to result in an increase in progression-free survival. The term, “effective amount”, as used herein, refers to an amount of a therapeutic agent effective to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects or to achieve a desired pharmacologic effect or therapeutic improvement with a reduced side effect profde. It is understood that “an effective amount” or “a therapeutically effective amount” can vary from subject to subject, due to variation in metabolism of the compound and any of age, weight, general condition of the subject, the condition being treated, the severity of the conditionbeing treated, and the judgment of the prescribing physician. Thus, it is not always possible to specify an exact “effective amount”. However, an appropriate “effective amount” in any individual case may be determined by one of ordinary skill in the art using routine experimentation. Where more than one therapeutic agent is used in combination, a “therapeutically effective amount” of each therapeutic agent or treatment approach can refer to an amount of the therapeutic agent that would be therapeutically effective when used on its own, or may refer to an adjusted (e.g., reduced) amount that is therapeutically effective by virtue of its combination with one or more additional therapeutic agents or treatment approaches.As used herein, the term “alkyl”, or “alkyl group”, refers to a saturated hydrocarbon radical containing 1 to 8 ((Ci-Cs)alkyl), 1 to 6 ((Ci-Cejalkyl), 1 to 4 ((Ci-C4)alkyl), or 5 to 8 ((Cs-Csjalkyl) carbons. In some embodiments, the saturated radical contains more than 8 carbons. An alkyl group is structurally similar to a noncyclic alkane compound modified by the removal of one hydrogen from the noncyclic alkane and the substitution therefore of a non- hydrogen group or radical. Alkyl group radicals can be branched or unbranched. Lower alkyl group radicals have 1 to 4 carbon atoms. Higher alkyl group radicals have 5 to 8 carbon atoms. Examples of alkyl, lower alkyl, and higher alkyl group radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, amyl, t-amyl, n-pentyl, n- hexyl, i-octyl and like radicals.As used therein, the term “PG” stands for protecting group, which is a functionality that is designed to protect certain chemical functional moieties, such as amines, hydroxyl, phenoxyl and / or acids, from certain reaction conditions. A skilled artisan would generally be familiar with this methodology and would consider “Greene's Protective Groups in Organic Synthesis” by Peter G. M. Wuts, Theodora W. Greene, First published: 10 April 2006, John Wiley & Sons, Inc.As used herein, the term “Ar” stands for an aromatic group, (i.e., an aromatic ring) such as aryls and heteroaryls. The term “aryl” refers to a hydrocarbon monocyclic, bicyclic, or tricyclic aromatic ring system. Aryl groups may be optionally substituted with one or more substituents. In some embodiments, 0, 1, 2, 3, 4, 5, or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like. The term “heteroaryl” refers to an aromatic 5-10 membered ring system where the heteroatoms are selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated). Heteroaryl groups may be optionally substituted with one or more substituents. In some embodiments, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include, but are not limited to, pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl,isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like. As used herein, the designations “C(=O),” “CO” and “C(O)” are used to indicate a carbonyl moiety. Examples of suitable carbonyl moieties include, but are not limited to, those found in ketones and aldehydes.As used herein, the term “cycloalkyl” refers to a hydrocarbon with 3-8 members ((C3-Cs)cycloalkyl), or 3-7 members ((C3-C7)cycloalkyl), or 3-6 members ((C3-C6)cycloalkyl), or 3-5 members ((C3-Cs)cycloalkyl), or 3-4 members ((C3-C4)cycloalkyl), and can be monocyclic or bicyclic. The ring may be saturated or may have some degree of unsaturation. In some cases, the degree of saturation encompasses aromatic compounds. Cycloalkyl groups may be optionally substituted with one or more substituents. In some embodiments, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, phenyl, and the like.As used herein, the term “heterocycle” refers to a nonaromatic 3-8 membered monocyclic ((C3-Cs)heterocycle), 7-12 membered bicyclic ((C7-Ci2)heterocycle), or 10-14 membered tricyclic ((Cio-Ci4)heterocycle)ring system comprising 1- 3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, S, B, P or Si, wherein the nonaromatic ring system is completely saturated. Included herein are also 7-12 membered bicyclic ((C7-Ci2)heterocycle), or 10-14 membered tricyclic ((C10-Ci4)heterocycle) ring system comprising 1-3 heteroatoms, wherein at least one of the rings is non-aromatic but the other ring systems can be aromatic. Heterocycloalkyl groups may be optionally substituted with one or more substituents. In some embodiments, 0, 1, 2, 3, or 4 atoms of each ring of a heterocycloalkyl group may be substituted by a substituent. Representative heterocycloalkyl groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolanyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, and the like.As used herein, the term “stereoisomer” refers to compounds which have identical chemical constitution, but differ with regards to the arrangement of the atoms or groups in space. These “stereoisomers” have a “stereogenic center”, which may be a chiral center. As used herein, the term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. As used herein, the term “diastereomers” refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers may have different physical properties, e.g., melting points, boiling points,spectral properties, and reactivity. Mixtures of diastereomers may separate under high-resolution analytical procedures such as electrophoresis and chromatography. As used herein, the term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wiley, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. The compounds of Formula I, as described herein, may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula I, including, but not limited to, diastereomers, enantiomers, and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present disclosure. Mixtures of stereoisomers may separate under high-resolution analytical procedures such as electrophoresis, chiral salt formation, and chromatography. For example, in some embodiments the compound of Formula I is 4-[131I]iodo-phenylalanine, and it will be understood that 4-[131I]iodo-phenylalanine refers to either the E- or the D-isomer at the a-carbon atom.As used herein, the term “pharmaceutically acceptable salt” includes any pharmaceutically acceptable salt, which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound of Formula I. In particular, the term “pharmaceutically acceptable salt” refers, without limitation, to derivatives of the compounds of Formula I wherein the compound is modified by converting an existing acid or base moiety to its salt form (e.g. by reacting the free base group with a suitable organic acid or inorganic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate and valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, ethylamine, and the like. It will be appreciated that a pharmaceutically acceptable salt may be present in amorphous form or in crystalline form.The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the compound of Formula I formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salt can be synthesised from the compound of Formula I which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of the compound of Formula I with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in, for example, Remington: The Science and Practice of Pharmacy, Adeboye Adejare and Joseph Remington (Ed), Academic Press, London, 23rdEdition, 2021; Stahl and Wermuth (2002) Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH; and Berge et al. (1977) Journal of Pharmaceutical Science, 66: 1-19, each of which is incorporated herein by reference in its entirety.Therapeutic Methods and UsesProvided herein are methods of treating a glioma. The methods may be applicable to the treatment of a glioblastoma, including a newly diagnosed glioblastoma, recurrent glioblastoma, and / or high-grade glioma.Gliomas are primary central nervous system (CNS) tumours. Based on the 2021 WHO classification, the three main types of gliomas in adults are isocitrate dehydrogenase (IDH)-mutant astrocytoma; IDH-mutant, lp / 19q-codeleted oligodendroglioma; and IDH wild-type glioblastoma. Other types of gliomas in adults include diffuse midline glioma, diffuse hemispheric glioma, and pilocytic astrocytoma. Some gliomas are more common in children. For example, the 2021 WHO classification includes four entities in the group of paediatric type low-grade gliomas: MYB / MYBL1 -altered diffuse astrocytoma; angiocentric glioma; polymorphous low-grade neuroepithelial tumor of the young; and mitogen-activated protein kinase pathway-altered diffuse low-grade glioma. Paediatric type high-grade gliomas include, for example, methylation of histone 3 (H3) on lysine 27 (H3K27)- altered diffuse midline glioma; glycine 34 of H3 (H3G34)-mutant diffuse hemispheric glioma; H3 wild-type, IDH wild-type paediatric type diffuse high-grade glioma; and paediatric type hemispheric glioma. It will be understood that the therapeutic methods described herein may effect a desirable or beneficial change in the health of a patient who has any type of a glioma known to a person skilled in the art.Gliomas in both adult and paediatric patients are associated with substantial morbidity and mortality. Recent advances have aided the understanding of the molecular pathogenesis and biology of these tumours, but this has not translated into significantly improved outcomes. In contrast, the present inventors have determined that advantageous treatment regimens using a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may provide a safe, tolerable, effective or reliable therapy for glioma patients. It was further determined that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) treatment may be advantageously combined with a nitrosourea chemotherapy; or with a nitrosourea chemotherapy and external beam radiotherapy; or with a nitrosourea chemotherapy and Temozolomide chemotherapy; or with a nitrosourea chemotherapy, Temozolomide chemotherapy, and external beam radiotherapy; to provide useful therapy options for patients with glioma, including glioblastoma, newly diagnosed glioblastoma, recurrent glioblastoma, and / or high-grade glioma.Accordingly, there is provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I. In some embodiments, the compound of Formula I is 4-L-[131I]iodo-phenylalanine.Accordingly, there is provided a method of treating a glioma comprising the administration of a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy and external beam radiotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy and external beam radiotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy.There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy.There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I, optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine, optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.It has been surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, administered at a therapeutically effective amount, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that a compound of Formula I, including 4-L-[131I]iodo-phenylalanine, optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioma, such as a glioblastoma.Those of ordinary skill in the art will appreciate that, as with most cancer therapies, the therapeutic methods described herein are not to be interpreted as, restricted to, or otherwise limited to a "cure" for cancer; rather the methods of treatment are directed to the use of thedescribed compositions to "treat" a cancer, i.e., to effect a desirable or beneficial change in the health of an individual who has cancer. Such benefits are recognized by skilled healthcare providers in the field of oncology and include, but are not limited to, a stabilization of patient condition, a decrease in tumour size (tumour regression), an improvement in vital functions (e.g., improved function of cancerous tissues or organs), a decrease or inhibition of further metastasis, a decrease in opportunistic infections, an increased survival, a decrease in pain, improved motor function, improved cognitive function, improved feeling of energy (vitality, decreased malaise), improved feeling of well-being, restoration of normal appetite, restoration of healthy weight gain, and combinations thereof. For example, the methods described herein may provide an increase in the overall survival of the patients, which can be monitored by survival follow-up phone calls at any suitable time interval(s), such as a 6-month, one-year or two-year survival. In one instance, the survival is a Progression Free Survival (PFS) from the date of the commencement of treatment to the date of progression or death for any cause, whichever comes first, assessed at a suitable time period, such as for example a period of 52 weeks. In addition or alternatively, a beneficial change in the health of a patient administered the method described herein may be assessed by an Objective Response Rate (ORR) at any suitable time interval(s) as defined by the Response Assessment in Neuro-Oncology (RANG) criteria. Further or alternatively, the therapeutic methods described herein may result in an improvement of a Quality of Life (QoL), for example a QoL as determined using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire and / or Quality of Life Questionnaire - Brain Neoplasm questionnaires, or any number of neurocognitive tests, such as, for example, Controlled Oral Word Association Test (COWA test), Hopkins Verbal Learning Test-Revised (HVLT-R test), or Trail Making Test (TMT). In addition or alternatively, a decrease in tumour size in an individual (e.g., as a result of the methods of treatment described herein) may be assessed by imaging methods known to a person skilled in the art before, during and / or after treatment administration. In addition or alternatively, an effect of the methods described herein may present as any morphological and / or metabolic changes indicative of tumour response using T1 gadolinium-enhanced Magnetic Resonance Imaging (MRI), O-2-18F-fluoroethyl-l-tyrosine ([18F]-FET) Positron Emission Tomography (PET), and / or computed tomography (CT) imaging. For example, any tumour regression or normalisation induced by employing the methods of this disclosure may be indicated by Sum of the Product of the Perpendicular Diameters (SPPD) as determined, for example, by contrast enhanced T1 MRI, and / or changes in parameters within the metabolic tumour volume (MTV), and / or tumour-to-brain ratios as determined by, for example, [18F]-FET-PET or computed tomography (CT) imaging.As discussed above, glioblastoma (glioblastoma multiforme, GBM; World Health Organization (WHO) grade IV astrocytoma) accounts for 60% to 70% of malignant gliomas and remains the most aggressive subtype of glioma. Glioblastomas for which the methods described herein may be applicable may include, for example, newly diagnosed, diagnosed, or recurrent glioblastomas, as well as high-grade gliomas (HGGs). Unexpectedly, it has been found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered at a therapeutically effective amount, provides an improved method of treating a glioblastoma. Similarly, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a glioblastoma. It has been further surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioblastoma.Accordingly, there is provided a method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to a patient in need thereof. There is also provided a method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosoureachemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In one example, the glioblastoma is a newly diagnosed glioblastoma. It will be appreciated that the term “newly diagnosed” refers to a newly identified glioblastoma. Accordingly, a “newly diagnosed” glioblastoma is not a recurrent glioblastoma. Therefore, any treatment that targets a “newly diagnosed” glioblastoma is considered a first-line therapy. Surprisingly, it has been found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered at a therapeutically effective amount, provides an improved method of treating a newly diagnosed glioblastoma. Similarly, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a newly diagnosed glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a newly diagnosed glioblastoma. It has been further surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a newly diagnosed glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a newly diagnosed glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a newly diagnosed glioblastoma.Accordingly, there is provided a method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to a patient in need thereof. There is also provided a method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosoureachemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a newly diagnosed glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In one example, the glioblastoma is a recurrent glioblastoma. It will be understood that “recurrent glioblastoma” refers to glioblastoma that has returned to the patient following a period of remission. Recurrent glioblastoma may be diagnosed by, for example, the appearance of residual tumour growth on imaging studies or the manifestation of associated clinical symptoms. Advantageously, it has been found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered at a therapeutically effective amount, provides an improved method of treating a recurrent glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a recurrent glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a recurrent glioblastoma. It has been further surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a recurrent glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a recurrent glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a recurrent glioblastoma.Accordingly, there is provided a method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to a patient in need thereof. There is also provided a method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a recurrent glioblastoma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In one example, the glioblastoma is high-grade glioma (HGG). It will be understood that “high-grade glioma” refers to gliomas of Grade 3 or Grade 4, based on how rapidly and / or aggressively the cancer cells duplicate. Generally, glioblastomas are considered high-grade gliomas, with glioblastomas typically designated as a Grade 4 glioma. Advantageously, it has been found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered at a therapeutically effective amount, provides an improved method of treating a high-grade glioma (HGG). It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a high-grade glioma (HGG). It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a high-grade glioma (HGG). It has been further surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a high-grade glioma (HGG). Further, it has been surprisingly found that a compound of Formula I(e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a high-grade glioma (HGG). Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a high-grade glioma (HGG).Accordingly, there is provided a method of treating a high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to a patient in need thereof. There is also provided a method of a high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a highgrade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In some embodiments, the high-grade glioma (HGG) is a recurrent high-grade glioma. For example, the methods described herein may be effective in the treatment of a recurrent IDH1 / 2 wildtype high-grade glioma (HGG).Accordingly, there is provided a method of treating a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) to a patient in need thereof. There is also provided a method of a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with anitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a recurrent high-grade glioma (HGG) comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In some embodiments, there is provided use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, for the treatment of glioma. In some embodiments, there is provided use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, in the treatment of glioma. In some embodiments, there is provided use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in the treatment of glioma.In some embodiments, there is provided a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, for use in the treatment of glioma. In some embodiments, there is provided a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, for use in the treatment of glioma. In some embodiments, there is provided a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, for use in the treatment of glioma.In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), in the manufacture of a medicament for the treatment of glioma. In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), in the manufacture of a medicament for the treatment of glioma, wherein the medicament is formulation for administration optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof. In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), in the manufacture of a medicament for the treatment of glioma, wherein the medicament is formulated for administration in combination with a nitrosourea chemotherapy. In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in the manufacture of a medicament for the treatment of glioma, wherein the medicament is formulated for administration in combination with a nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy.In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and a nitrosourea, in the manufacture of a medicament for the treatment of glioma. In some embodiments, there is provided the use of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), a nitrosourea, and Temozolomide, in the manufacture of a medicament for the treatment of glioma.Compounds of Formula IIt has been surprisingly found that compounds of Formula I interact with (i.e., are taken up by) the L-type / large neutral amino acid transporter 1, LAT1 (SLC7A5), which has repeatedly been found to be overexpressed in a vast array of cancers including breast cancer, prostate cancer, lung cancer, bladder cancer, and bone cancer, amongst others. LAT1 is also known to be expressed in brain tumours, including glioblastoma.LAT1 serves as an important route for essential amino acid entry into cells, a critical component for tumerous cell proliferation. It has been postulated that inhibitors, or blockers, of LAT1 may lead to decreased uptake of essential amino acids by tumorous cells, and therefore decreased tumerous cell proliferation. In this way, it is understood that inhibitors of LAT1, such as 4-L-[131I]iodo-phenylalanine, may exert a chemotherapeutic effect.Accordingly, the methods described herein involve the administration of a compound of Formula I:OFormula I.Compounds of Formula I are disclosed in WO2025122904, the content of which is incorporated in full herein.In some embodiments, the compound of Formula I is:OFormula I;whereinX is selected from the group consisting of -O-, -N(H)-, -N[(C3-C6)cycloalkyl]-, and -N[(Ci-C6)alkyl]-;R1and R2are each independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C7)cycloalkyl, or X and R1together form a (C3-Cs)heterocycle;R3is selected from the group consisting of -I,

[123] I,

[124] I,

[125] I, and

[131] I;R4is selected from the group consisting of -H, -F, or

[18] F;R5is selected from the group consisting of -PG, -(Ci-C6)alkyl, and -(C3-C6)cycloalkyl; R6and R7are each independently selected from the group consisting of -H, -PG, -CH2 Ar, -(Ci-C4)alkyl, and -(C3-C6)cycloalkyl, or R6and R7together form a (C3-C5)heterocycle;wherein, if present, each PG is independently a protecting group;m is 0, 1, 2, or 3;n is 0, 1, or 2;or a pharmaceutically acceptable salt or stereoisomer thereof.In some embodiments, X is selected from the group consisting of -O-, -N(H)-, N[(C3-C6)cycloalkyl]-, and -N[(Ci-C6)alkyl]-. In one example, X is -O-. In one example, X is -N(H)-. In one example, X is -N[(C3-C6)cycloalkyl]-. In one example, X is -N[(Ci-C6)alkyl]-.In some embodiments, R1is selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C7)cycloalkyl. In one example, R1is -H. In one example, R1is -PG. In one example, R1is -CFhAr. In one example, R1is -(Ci-C4)alkyl. In one example, R1is -(C3-C7)cycloalkyl.In some embodiments, X and R1together form a (C3-C5)heterocycle.In some embodiments, R2is selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C7)cycloalkyl. In one example, R2is -H. In one example, R2is -PG. In one example, R2is -CFhAr. In one example, R2is -(Ci-C4)alkyl. In one example, R2is -(C3-C7)cycloalkyl.In some embodiments, R3is selected from the group consisting of -I,

[123] I,

[124] I,

[125] I, and

[131] I. In one example, R3is -I. In some embodiments, R3is a radioisotope of -I, including, but not limited to,

[123] I,

[124] I,

[125] I, and

[131] I. In one example, R3is

[123] I. In one example, R3is

[124] I. In one example, R3is

[125] I. In one example, R3is

[131] I.In some embodiments, R4is selected from the group consisting of -H, -F, or

[18] F. In one example, R4is -H. In one example, R4is -F. In some embodiments, R4is a radioisotope of -F. In one example, R4is

[18] F.In some embodiments, R5is selected from the group consisting of -PG, -(Ci-C6)alkyl, and -(C3-C6)cycloalkyl. In one example, R5is -PG. In one example, R5is -(Ci-C6)alkyl. In one example, R5is -(C3-C6)cycloalkyl.In some embodiments, R6is independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C6)cycloalkyl. In one example, R6is -H. In one example, R6is -PG. In one example, R6is -CFhAr. In one example, R6is -(Ci-C4)alkyl. In one example, R6is -(C3-C6)cycloalkyl.In some embodiments, R7is independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C6)cycloalkyl. In one example, R7is -H. In one example, R7is -PG. In one example, R7is -CFhAr. In one example, R7is -(Ci-C4)alkyl. In one example, R7is -(C3-C6)cycloalkyl.In some embodiments, R6and R7together form a (C3-Cs)heterocycle.In some embodiments, m is 0, 1, 2, or 3. In one example, m is 0. It will be appreciated that, when m is 0, the F (fluorine) substituent is not present. In one example, m is 1. In one example, m is 2. In one example, m is 3.In some embodiments, n is 0, 1, or 2. In one example, is 0. It will be appreciated that, when n is 0, the -R5O substituent is not present. In one example, n is 1. In one example, n is 2.In some embodiments, if present, PG is selected from the group consisting of a protecting group for an amine moiety, a hydroxyl moiety, or an acid functionality. In some embodiments, PG is a protecting group for an amine moiety (e.g., primary amine, secondary amine). In some embodiments, PG is a protecting group for a hydroxyl moiety (e.g., -OH). In some embodiments, PG is a protecting group for a carboxylic acid moiety (e.g., -COOH). In some embodiments, PG is a protecting group for a carboxamide moiety (e.g., -CONH2, -CONHR). In some embodiments, PG is a protecting group for an amine moiety selected from the group consisting of -Boc, -benzyl, -Cbz, FMoc, Teoc, Troc, SEM, MOM, TPDPS, TIPS, benzhydryl, and trityl.In one example, X is -O-, R1is -H, R2is -H, R3is

[131] I, R4is -H, R6is -H, R7is -H, m is 0, and n is 0, and the compound of Formula I is:o4-

[1311] iodo-pheny lalanine.In one example, the compound of Formula I is 4-L-[131I]iodo-phenylalanine. In one example, the compound of Formula I is 4-D-[131I]iodo-phenylalanine.The methods described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs) of the compound of Formula I. The compounds of Formula I may be in the form of pharmaceutically acceptable salts. Active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure.In some embodiments, the compounds of Formula I may be used as pharmaceutically acceptable salts. The type of pharmaceutical acceptable salts include, but are not limited to: (1) acid addition salts, formed by reacting a free base form of the compound with a pharmaceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzene sulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like; (2) salts formed when an acidic proton present in the compound is replaced by a metal ion, e.g., an alkali metal ion ( e.g. lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminium ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine, and the like.4-'L-

[1311] iodo-phenylalanineOf those compounds of Formula I, 4-L-[131I]iodo-phenylalanine, also referred to as131I-IPA, 1311-Iodofalan, lodofalan 1-131, and TLX101, is a radiolabelled synthetic amino acid having the structure:OStructure of 4-L-[131I]iodo-phenylalanine.4-L-[131I]iodo-phenylalanine interacts with (i.e., is taken up by) the L-type / large neutral amino acid transporter 1, LAT1 (SLC7A5).The compounds of Formula I are understood to be able to rapidly cross the blood-brain barrier (BBB). In particular, 4-L-[131I]iodo-phenylalanine is known to be able to rapidly cross the blood-brain barrier (BBB). As a result, the compounds of Formula I, and particularly 4-L-[131I]iodo-phenylalanine, are able to access glioblastoma tumour cells where they can exert a chemotherapeutic effect. As a result of its high uptake across the BBB, chemotherapy with the compounds of Formula I, (e.g., 4-L-[131I]iodo-phenylalanine) advantageously results in very little peripheral dosimetry. The compounds of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) are therefore a highly useful chemotherapy tool in the treatment of glioblastoma.The methods described herein involve administration of a compound of Formula I. It has been surprisingly found that a compound of Formula I, administered at a therapeutically effective amount, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that a compound of Formula I, administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that a compound of Formula I, administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that a compound of Formula I, administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that a compound of Formula I, administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that a compound of Formula I, optionally administered in combination with a nitrosourea chemotherapy, externalbeam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioma, such as a glioblastoma.In particular, the methods described herein involve administration of the 4-L-[131I]iodo-phenylalanine. It has been surprisingly found that 4-L-[131I]iodo-phenylalanine, administered at a therapeutically effective amount, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has been further surprisingly found that 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that 4-L-[131I]iodo-phenylalanine, administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that 4-L-[131I]iodo-phenylalanine, optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioma, such as a glioblastoma.Accordingly, there is provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I, optionally in combination with a nitrosoureachemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In particular, accordingly, there is provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine, optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered intravenously. In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as an intravenous infusion. For example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered using an intravenous cannula. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered intravenously via an automated infusion system, which may help to provide protection against radiation to the treatment personnel.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in a therapeutically effective amount sufficient to treat the glioma (e.g., the glioblastoma). Where the methods of treatment described herein comprise the administration of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) alone, the treatment may be referred to as a “monotreatmenf ’ or a “monotherapy”.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in an amount sufficient to treat the glioma (e.g., the glioblastoma) when administered in combination with a nitrosourea chemotherapy. In some other embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in an amountsufficient to treat the glioma (e.g., the glioblastoma) when administered in combination with a nitrosourea chemotherapy and external beam radiotherapy. In some other embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in an amount sufficient to treat the glioma (e.g., the glioblastoma) when administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy. In some other embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in an amount sufficient to treat the glioma (e.g., the glioblastoma) when administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy. Where the methods of treatment described herein comprise the administration of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with any therapy selected from a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or a mixture thereof, the treatment may be referred to as a “combination treatment” or a “combination therapy”.The amount of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) administered is quantified by its radiation dose (i.e., radioactive dose level), as measured in Becquerel (Bq). As would be understood by the skilled person, one Becquerel is defined as the activity of a quantity of radioactive material in which one nucleus decays per second.In some embodiments, the compound of Formula I is administered in an amount of at least about 0.5 GBq, at least about 1 GBq, at least about 1.5 GBq, at least about 2 GBq, at least about 4 GBq, at least about 6 GBq, at least about 8 GBq, at least about 10 GBq, at least about 12 GBq, at least about 14 GBq, at least about 16 GBq, at least about 18 GBq, or at least about 20 GBq. In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, or at least about 12 GBq.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of at least about 0.5 GBq, at least about 1 GBq, at least about 1.5 GBq, at least about 2 GBq, at least about 4 GBq, at least about 6 GBq, at least about 8 GBq, at least about 10 GBq, at least about 12 GBq, at least about 14 GBq, at least about 16 GBq, at least about 18 GBq, or at least about 20 GBq. In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, or at least about 12 GBq.In some embodiments, the compound of Formula I is administered in an amount of less than about 0.5 GBq, less than about 1 GBq, less than about 1.5 GBq, less than about 2 GBq, less than about 4 GBq, less than about 6 GBq, less than about 8 GBq, less than about 10 GBq, lessthan about 12 GBq, less than about 14 GBq, less than about 16 GBq, less than about 18 GBq, or less than about 20 GBq.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of less than about 0.5 GBq, less than about 1 GBq, less than about 1.5 GBq, less than about 2 GBq, less than about 4 GBq, less than about 6 GBq, less than about 8 GBq, less than about 10 GBq, less than about 12 GBq, less than about 14 GBq, less than about 16 GBq, less than about 18 GBq, or less than about 20 GBq.In some embodiments, the compound of Formula I is administered in an amount of between about 0.5 GBq and about 20 GBq, between about 1 GBq and about 18 GBq, between about 2 GBq and about 18 GBq, between about 2 GBq and about 16 GBq, between about 2 GBq and about 12 GBq, between about 2 GBq and about 10 GBq, between about 2 GBq and about 6 GBq, between about 4 GBq and about 14 GBq, or between about 8 GBq and about 12 GBq. In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of about 2 GBq to about 16 GBq, about 2 GBq to about 14 GBq, about 2 GBq to about 12 GBq, about 2 GBq to about 10 GBq, about 2 GBq to about 8 GBq, about 2 GBq to about 7 GBq, about 2 GBq to about 6 GBq, about 2 GBq to about 5 GBq, or about 2 GBq to about 4 GBq. In one example, the compound of Formula I is administered in an amount of between about 2 GBq and about 18 GBq. In one example, the compound of Formula I is administered in an amount of between about 2 GBq and about 8 GBq. In one example, the compound of Formula I is administered in an amount of between about 2 GBq and about 12 GBq, between about 2 GBq and about 10 GBq, between about 2 GBq and about 8 GBq, or between about 2 GBq and about 6 GBq.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of between about 0.5 GBq and about 20 GBq, between about 1 GBq and about 18 GBq, between about 2 GBq and about 18 GBq, between about 2 GBq and about 16 GBq, between about 2 GBq and about 12 GBq, between about 2 GBq and about 10 GBq, between about 2 GBq and about 6 GBq, between about 4 GBq and about 14 GBq, or between about 8 GBq and about 12 GBq. In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of about 2 GBq to about 16 GBq, about 2 GBq to about 14 GBq, about 2 GBq to about 12 GBq, about 2 GBq to about 10 GBq, about 2 GBq to about 8 GBq, about 2 GBq to about 7 GBq, about 2 GBq to about 6 GBq, about 2 GBq to about 5 GBq, or about 2 GBq to about 4 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered in an amount of between about 2 GBq and about 18 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered in an amount of between about 2 GBq and about 8 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered in an amount of between about 2 GBq and about 12 GBq, between about 2 GBqand about 10 GBq, between about 2 GBq and about 8 GBq, or between about 2 GBq and about 6 GBq.The methods of treatment described herein may provide for the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in any number of doses (or fractions) and at any suitable time so as to maximise the therapeutic efficacy of the treatment, including a combination treatment. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered in any number of doses (or fractions) at any number of timepoints (e.g., days from commencement of treatment) so as to provide maximal therapeutic efficacy of the treatment, including a combination treatment. That is, selecting the number of doses (or fractions) of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) administered, and the particular timepoints of administration of each dose (or fraction) throughout the duration of treatment, may further maximise the therapeutic efficacy of the treatment, including a combination treatment.Accordingly, the methods of treatment described herein may involve the administration of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) as a single dose, or alternatively as more than one dose. As will be appreciated by a person skilled in the art, the stated amounts of administered compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum or a cumulative dose, also referred to as a total dose, of two or more fractions or doses. For example, an amount of 6 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of three equal doses of 2 GBq, an amount of 9 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of three equal doses of 3 GBq, and an amount of 12 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of three equal doses of 4 GBq. In other examples, an amount of 6 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of a dose of 4 GBq and a dose of 2 GBq, an amount of 9 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of a dose of 6 GBq and a dose of 3 GBq, and an amount of 12 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of a dose of 8 GBq and a dose of 4 GBq. In other examples, an amount of 6 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of two equal doses of 3 GBq, an amount of 8 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of two equal doses of 4 GBq, an amount of 10 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of two equal doses of 5 GBq, and an amount of 12 GBq of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be a sum of two equal doses of 6 GBq.In embodiments, the compound of Formula I is administered as a single dose. In one example, the compound of Formula I is administered as a single dose of between about 2 GBqand about 18 GBq. In one example, the compound of Formula I is administered as a single dose of between about 2 GBq and about 12 GBq. In another example, the compound of Formula I is administered as a single dose of between about 2 GBq and about 8 GBq.In embodiments, the 4-L-[131I]iodo-phenylalanine is administered as a single dose. In one example, the 4-L-[131I]iodo-phenylalanine is administered as a single dose of between about 2 GBq and about 18 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered as a single dose of between about 2 GBq and about 12 GBq. In another example, the 4-L-[131I]iodo-phenylalanine is administered as a single dose of between about 2 GBq and about 8 GBq.In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as two, three, four, five, six, seven, eight, or more doses (or fractions). Each dose may administer a substantially equal dose of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), or may administer a substantially unequal dose of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as two, three, four, five, six, seven, eight, or more substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as two substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as three substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as four substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as five substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as six substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as seven substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as eight substantially equal doses. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as 10 substantially equal doses.In some embodiments, the compound of Formula I is administered in an amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq, 8 GBq, 10 GBq, 12 GBq, 16 GBq, 17 GBq, or 18 GBq. In one example, the compound of Formula I is administered in an amount of at least about 2 GBq. This amount may be as an individual dose or a cumulative dose (i.e., the summation of doses provided over two or more administrations). In some preferred embodiments, the compound of Formula I is administered in an individual dose amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq, 7 GBq, 8 GBq, 9 GBq, 10 GBq, 11 GBq, 12 GBq, 13 GBq, 14 GBq, 15 GBq, 16 GBq, or 18 GBq. In some preferred embodiments, the compound of Formula I is administered in a cumulative dose amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq,7 GBq, 8 GBq, 9 GBq, 10 GBq, 11 GBq, 12 GBq, 13 GBq, 14 GBq, 15 GBq, 16 GBq, or 18 GBq. In one example, the compound of Formula I is administered in a cumulative dose amount of about 6 GBq.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq, 8 GBq, 10 GBq, 12 GBq, 16 GBq, 17 GBq, or 18 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered in an amount of at least about 2 GBq. This amount may be as an individual dose or a cumulative dose (i.e., the summation of doses provided over two or more administrations). In some preferred embodiments, the 4-L-[131I]iodo-phenylalanine is administered in an individual dose amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq, 7 GBq, 8 GBq, 9 GBq, 10 GBq, 11 GBq, 12 GBq, 13 GBq, 14 GBq, 15 GBq, 16 GBq, or 18 GBq. In some preferred embodiments, the 4-L-[131I]iodo-phenylalanine is administered in a cumulative dose amount of at least about 2 GBq, 3 GBq, 4 GBq, 5 GBq, 6 GBq, 7 GBq, 8 GBq, 9 GBq, 10 GBq, 11 GBq, 12 GBq, 13 GBq, 14 GBq, 15 GBq, 16 GBq, or 18 GBq. In one example, the 4-L-[131I]iodo-phenylalanine is administered in a cumulative dose amount of about 6 GBq.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 1 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 2 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 2 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 4 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 3 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 6 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 4 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 8 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 5 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 10 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 6 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 12 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 7 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 14 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 8 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 16 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of about 9 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 18 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as twosubstantially equal doses of about 2 GBq to about 8 GBq per dose. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses of 3 GBq to 7 GBq per dose. In embodiments, the first dose of 4-L-[131I]iodo-phenylalanine is administered at least a week prior to commencement of external beam radiotherapy, and the second dose being administered after completion (e.g., cessation) of external beam radiotherapy.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses. In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 0.67 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 2 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 1 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 3 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 2 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 6 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 2.67 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 8 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 3 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 9 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 3.33 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 10 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of 4 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 12 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of 5 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 15 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of 6 GBq (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 18 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses of about 2 GBq to about 7 GBq per dose.In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular or an irregular time interval of from one week to ten weeks, from one week to nine weeks, from one week to eight weeks, from one week to seven weeks, from one week to six weeks, from one week to five weeks, from one week to four weeks, from one week to three weeks, from one week to two weeks, or at a time interval of about one week. For example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered at a regular time interval of from about two weeks to about ten weeks; from about two weeks to about eight weeks, from about two weeks to about six weeks, or from about two weeks to about four weeks.In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular or an irregular time interval of about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, or about ten weeks. In embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular or an irregular time interval of about four weeks, about five weeks, or about six weeks. For example, the 4-L-[131I]iodo-phenylalanine may be administered at a regular interval of six weeks, such that for example the 4-L-[131I]iodo-phenylalanine is administered on day 1 and day 43 of the treatment, or on day 1, day 43, and day 85 of the treatment, or on day 1, day 43, day 85, and day 127 of the treatment.In some instances, the methods described herein comprise administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination.In some embodiments where the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in combination with external beam radiotherapy, the one or more dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) described above is administered prior to commencement of external beam radiotherapy. In some embodiments, the one or more dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days orweeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose.In some embodiments where the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in combination with external beam radiotherapy, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) described above are administered in parallel with external beam radiotherapy. That is, the one or more doses of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy may be administered, for example, on the same day or within the same suitable time interval during the treatment period. For example, the one or more doses of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered within some hours after administration of external beam radiotherapy. In such parallel administration, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy may be administered at any suitable time intervals, such as e.g. every 1-10 days, throughout the treatment period. In some embodiments, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In some embodiments, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the commencement of the methods of treatment described herein.In some embodiments where the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered in combination with external beam radiotherapy, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) are administered prior to commencement of and / or after completion (e.g., cessation) of external beam radiotherapy. In other words, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered sequentially with external beam radiotherapy. For example, in some embodiments, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) are administered after completion (e.g., cessation) of external beam radiotherapy. For example, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered within several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, the one or more doses of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) areadministered within one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered after completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered within several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered within several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks after the completion (e.g., cessation) of external beam radiotherapy.The methods of treatment described herein may involve the administration of a single dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) being administered at any time point (e.g., days from commencement of treatment) throughout the duration of treatment. In the instance where administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) does not commence on day one, it will be understood that administration of external beam radiotherapy, or the administration of a nitrosourea chemotherapy, or Temozolomide chemotherapy, will signify the commencement of the methods of treatment described herein (i.e., day one). In one example, a single dose of 4-L-[131I]iodo-phenylalanine is administered between day one and day 42, between day one and day 35, day one and day 28, day one and day 21, day one and day 14, or day one and day seven, from the commencement of the methods of treatment described herein. Further, as will be appreciated by the person skilled in the art, administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) on the day of commencement of the methods of treatment described herein may be taken as administration on “day zero”. Accordingly, in one example, a single dose of 4-L-[131I]iodo-phenylalanine is administered between day zero and day 42, between day zero and day 35, day zero and day 28, day zero and day 21, day zero and day 14, or day zero and day seven, from the commencement of the methods of treatment described herein.In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day zero from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day one from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day two from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day three from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day four from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day five from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day six from commencement of the methods of treatment described herein. In one example, 4-L-[131I]iodo-phenylalanine is administered as a single dose on day seven (i.e., one week) from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at any two or more timepoints (e.g., days from commencement of treatment) throughout the duration of treatment. In one example, compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a further dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as three substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as four substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about oneweek, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as five substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as six substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose, with each dose administered at regular intervals over the treatment period.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose for a duration of at least about one week, at least about two weeks, at least about three weeks, at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about ten weeks, at least about eleven weeks, at least about twelve weeks, at least about thirteen weeks, at least about fourteen weeks, at least about fifteen weeks, or at least about sixteen weeks from commencement of treatment. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose for a duration of at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about ten weeks, at least about eleven weeks, or at least about twelve weeks from commencement of treatment.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular time interval of about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks,about eight weeks, about nine weeks, about ten weeks, about eleven weeks, or about twelve weeks. For example, a second dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered about four weeks after the first dose, and a third dose may be administered about four weeks after the second dose. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular time interval of from one week to twelve weeks (e.g., 79 days), from one week to eleven weeks (e.g., 72 days), from one week to ten weeks (e.g., 65 days), from one week to nine weeks (e.g., 58 days), from one week to eight weeks (e.g., 51 days), from one week to seven weeks (e.g., 44 days), from one week to six weeks (e.g., 37 days), from one week to five weeks (e.g., 30 days), from one week to four weeks (e.g., 23 days), from one week to three weeks (e.g., 16 days), from one week to two weeks (e.g., 9 days), or at a time interval of about one week (e.g., 5 days). In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at a regular time interval of from about two weeks to about ten weeks (e.g., 65 days), from about two weeks to about eight weeks (e.g., 51 days), from about two weeks to about six weeks (e.g., 37 days), or from about two weeks to about four weeks (e.g., 23 days). For example, a second dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered 23 days after the first dose, and a third dose may be administered 23 days after the second dose.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at an irregular time interval of about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about eleven weeks, or about twelve weeks. For example, a second dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered about four weeks after the first dose, and a third dose may be administered about one week, about two weeks, about three weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about eleven weeks, or about twelve weeks after the second dose. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose at an irregular time interval of from one week to twelve weeks (e.g., 79 days), from one week to eleven weeks (e.g., 72 days), from one week to ten weeks (e.g., 65 days), from one week to nine weeks (e.g., 58 days), from one week to eight weeks (e.g., 51 days), from one week to seven weeks (e.g., 44 days), from one week to six weeks (e.g., 37 days), from one week to five weeks (e.g., 30 days), from one week to four weeks (e.g., 23 days), from one week to three weeks (e.g., 16 days), from one week to two weeks (e.g., 9 days), or at a time interval of about one week (e.g., 5 days). In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) isadministered as more than one dose at an irregular time interval of from about two weeks to about ten weeks (e.g., 65 days), from about two weeks to about eight weeks (e.g., 51 days), from about two weeks to about six weeks (e.g., 37 days), or from about two weeks to about four weeks (e.g., 23 days). For example, a second dose of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered 23 days after the first dose, and a third dose may be administered 51 days after the second dose.Periods of administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) as more than one dose at a regular time interval may alternate with periods of administration of compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) at an irregular time interval during the course of the treatment.In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein.In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day zero from commencement of the methods of treatment described herein. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two doses on days zero and 46, from commencement of treatment. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses on days zero and 46, from commencement of treatment. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two doses on days one and seven, from commencement of treatment. In one example, the 4-L-[131I]iodo-phenylalanine is administered as two substantially equal doses on days one and seven, from commencement of treatment. In one example, the 4-L-[131I]iodo-phenylalanine is administered as three doses on days one, seven, and 14, from commencement of treatment.In one example, the 4-L-[131I]iodo-phenylalanine is administered as three substantially equal doses on days one, 43, and 85, from commencement of treatment. In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 0.67 GBq per dose on days one, seven, and 14, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 2 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 2 GBq per dose on days one, 43, and 85, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 6 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 2.67 GBq per dose on days one, 43, and 85, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 8 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 3 GBqper dose on days one, seven, and 14, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 9 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 3.33 GBq per dose on days one, 43, and 85, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 10 GBq). In one example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 4 GBq per dose on days one, 43, and 85, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 12 GBq). In yet another example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 2 GBq per dose on days one, 43, and 85, or on days one, 29 and 57, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 6 GBq). In yet another example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 3 GBq per dose on days one, 43, and 85, or on days one, 29 and 57, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 9 GBq). In yet another example, the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of about 4 GBq per dose on days one, 43, and 85, or on days one, 29 and 57, from commencement of treatment (i.e., a total dose of 4-L-[131I]iodo-phenylalanine of about 12 GBq).NitrosoureasNitrosoureas are a class of alkylating agents that exert their mechanism of action through the alkylation of DNA strands, which is believed to result in DNA damage and cellular death.In some embodiments, the methods described herein involve administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy. It has been surprisingly found that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioma, such as a glioblastoma.Accordingly, there is provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy to a patient in need thereof. There is further provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is further provided method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.Non-limiting examples of nitrosoureas suitable for use in the methods of treatment described herein include Lomustine, Carmustine, Fotemustine, Streptozocin, Chlorourethrin, Nimustine, Ranimustine, 1 -Methylnitrosourea, and combinations thereof. In some embodiments, the nitrosourea is selected from the group consisting of Lomustine, Carmustine, Fotemustine, and combinations thereof.In some embodiments, the nitrosourea is Lomustine:Lomustine.Lomustine (CCNU; l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea) is an orally administered chemotherapy agent.In some embodiments, the nitrosourea is Carmustine:oCarmustine.Carmustine (BCNU; l,3-bis(2-chlorocthyl)-l -nitrosourea) is an intravenously administered nitrosourea that may be administered, for example, at a dose of about 70 mg / m2to about 300 mg / m2. For example, Carmustine may be used with two schedules of administration: 80 mg / m2on days 1-3 every 6 weeks or 240 mg / m2on day 1 every 6 weeks.In some embodiments, the nitrosourea is Fotemustine:Fotemustine.Fotemustine ((RS)-diethyl (l-{ [(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl) phosphonate) is an intravenously administered nitrosourea that may be administered, for example, at a dose of about 70 to about 100 mg / m2. For example, Fotemustine may be given at 75 mg / m2on days 1-8-15, followed by maintenance with 100 mg / m2every 3 weeks.In some embodiments, the nitrosourea is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I.In some embodiments, the nitrosourea is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine.In some embodiments, the nitrosourea is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I and external beam radiotherapy.In some embodiments, the nitrosourea is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine and external beam radiotherapy.In some embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I and Temozolomide chemotherapy.In some embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine and Temozolomide chemotherapy.In some other embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I, a nitrosourea chemotherapy, and Temozolomide chemotherapy.In some other embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine, a nitrosourea chemotherapy, and Temozolomide chemotherapy.The methods of treatment described herein may provide for the administration of the nitrosourea in any number of doses and at any suitable time so as to maximise the therapeutic efficacy of the combination treatment. Typically, the nitrosourea is administered once every few weeks throughout the duration of the methods of treatment described herein. In one example, the nitrosourea is administered once every six weeks throughout the duration of the methods of treatment described herein.The nitrosourea may be administered daily for a duration of one day, seven days, 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, 56 days, 63 days, 70 days, 77 days, 84 days, 91 days, 98 days or more, from the commencement of treatment. In one example, the nitrosourea is administered every 42 days (e.g., six weeks) from the commencement of treatment (e.g., from the first dose of the nitrosourea).The nitrosourea may be administered once weekly, twice weekly, three times weekly, four times weekly, five times weekly, or six times weekly. In some embodiments, the nitrosourea is administered once every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every nine weeks, or every ten weeks. In one example, the nitrosourea is administered once every six weeks, for example on days 1, 43 and 85 (e.g., six weeks) of the treatment.In some embodiments, the nitrosourea is administered at the same time interval as the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In some embodiments, the nitrosourea is administered on the same day or days as the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In some embodiments, the nitrosourea is administered for at least the same duration of time as the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). For example, the 4-L-[131I]iodo-phenylalanine and the nitrosourea may be administered on days 1, 43, and 85 of the treatment.In some embodiments, the nitrosourea is administered prior to the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). For example, the nitrosourea may be administered on days 1, 43, and 85 of the treatment, and the 4-L-[131I]iodo-phenylalanine may be administered on days 85, 113, and 141 of the treatment. In another example, the nitrosourea may be administered on days 1, 43, and 85 of the treatment, and the 4-L-[131I]iodo-phenylalanine may be administered on days 113, 141, and 169 of the treatment. In some embodiments, the nitrosourea is administered after the commencement of the administration of the 4-L-[131I]iodo-phenylalanine. For example, the 4-L-[131I]iodo-phenylalanine may be administered on days 1, 29, and 57 of the treatment, and the nitrosourea may be administered on days 57, 99, and 141 of the treatment. In some embodiments, the nitrosourea is administered after the completion (e.g., cessation) of the administration of the 4-L-[131I]iodo-phenylalanine. For example, the 4-L-[131I]iodo-phenylalanine may be administered on days 1, 29, and 57 of the treatment, and the nitrosourea may be administered on days 85, 113, and 141 of the treatment. In any such embodiments, the administration of the 4-L-[131I]iodo-phenylalanine and the nitrosourea may be separated by a treatment break. In some instances, a treatment break is about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about eleven weeks, or about twelve weeks from the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) administration or the nitrosourea administration, whichever occurs first.The nitrosourea may be administered in an amount of 1 mg / m2to 500 mg / m2, per day. In some embodiments, the nitrosourea is administered in an amount of at least about 10 mg / m2, at least about 15 mg / m2, at least about 20 mg / m2, at least about 25 mg / m2, at least about 30 mg / m2, at least about 35 mg / m2, at least about 40 mg / m2, at least about 45 mg / m2, at least about 50 mg / m2, at least about 55 mg / m2, at least about 60 mg / m2, at least about 65 mg / m2, at least about 70 mg / m2, at least about 75 mg / m2, at least about 80 mg / m2, at least about 85 mg / m2, at least about 90 mg / m2, at least about 95 mg / m2, at least about 100 mg / m2, at least about 105 mg / m2, at least about 110 mg / m2, at least about 115 mg / m2, at least about 120 mg / m2, at least about 125 mg / m2, at least about 130 mg / m2, at least about 135 mg / m2, at least about 140 mg / m2, at least about 145 mg / m2, or at least about 150 mg / m2, per day. In some embodiments, the nitrosourea is administered in an amount of at least about 175 mg / m2, at least about 200 mg / m2, at least about 250 mg / m2, or at least about 300 mg / m2, per day. In some embodiments, the nitrosourea is administered in an amount of less than about 300 mg / m2, less than about 250 mg / m2, less than about 200 mg / m2, less than about 150 mg / m2, less than about 100 mg / m2, less than about 75 mg / m2, less than about 50 mg / m2, or less than about 25 mg / m2, per day. In some embodiments, the nitrosourea is administered in an amount of about 50 mg / m2, about 75 mg / m2, about 100 mg / m2, about 125 mg / m2, about 150 mg / m2, about 175 mg / m2, about 200 mg / m2, about 250 mg / m2, or about 300 mg / m2, per day. In some embodiments, the nitrosourea is administered in an amount of between about 25 mg / m2and about 300 mg / m2, between about 50 mg / m2and about 250 mg / m2, or between about 50 mg / m2and about 200 mg / m2, per day. In one example, the nitrosourea is administeredin an amount of between about 50 mg / m2and about 200 mg / m2, per day. In some such embodiments, the nitrosourea is selected from Lomustine, Carmustine, Fotemustine, or a mixture thereof.In some embodiments, the nitrosourea is Carmustine, administered in an amount of at least about 60 mg / m2, at least about 70 mg / m2, at least about 80 mg / m2, at least about 90 mg / m2, at least about 100 mg / m2, at least about 110 mg / m2, at least about 120 mg / m2, at least about 130 mg / m2, at least about 140 mg / m2, or at least about 150 mg / m2, at least about 160 mg / m2, at least about 170 mg / m2, at least about 180 mg / m2, at least about 190 mg / m2, at least about 200 mg / m2, at least about 210 mg / m2, at least about 230 mg / m2, at least about 240 mg / m2, at least about 250 mg / m2, at least about 260 mg / m2, at least about 270 mg / m2, at least about 280 mg / m2, at least about 290 mg / m2, or at least about 300 mg / m2, per day.In some embodiments, the methods of treatment described herein include the administration of the Carmustine once weekly, twice weekly, three times weekly, four times weekly, five times weekly, or six times weekly. In some embodiments, the Carmustine is administered once every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every nine weeks, or every ten weeks. In one example, the Carmustine is administered once every six weeks, for example on days 1, 43 and 85 of the treatment.In some embodiments, the methods of treatment described herein include the administration of the Carmustine in an amount of at least about 80 mg / m2, on days 1-3 every six weeks or 240 mg / m2on day 1 every six weeks.In some embodiments, the nitrosourea is Fotemustine, administered in an amount of at least about 50 mg / m2, at least about 55 mg / m2, at least about 60 mg / m2, at least about 65 mg / m2, at least about 70 mg / m2, at least about 75 mg / m2, at least about 80 mg / m2, at least about 85 mg / m2, at least about 90 mg / m2, at least about 95 mg / m2, at least about 100 mg / m2, at least about 105 mg / m2, at least about 110 mg / m2, at least about 115 mg / m2, or at least about 120 mg / m2, per day.In some embodiments, the methods of treatment described herein include the administration of the Fotemustine once weekly, twice weekly, three times weekly, four times weekly, five times weekly, or six times weekly. In some embodiments, the Fotemustine is administered once every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every nine weeks, or every ten weeks. In one example, the Fotemustine is administered once every week, for example on days 1, 8 and 15 of the treatment. In another example, the Fotemustine is administered once every two weeks, for example on days 1, 15, 29, 43 and 57 of the treatment. In another example, the Fotemustine is administered once every two weeks, for example on days 1, 15, 30, 45 and 60 of the treatment.In some embodiments, the methods of treatment described herein include the administration of the Fotemustine in an amount of at least about 75 mg / m2, on days 1, 15, 30, 45 and 60 of the treatment.In some embodiments, the nitrosourea is Lomustine, administered in an amount of at least about 10 mg / m2, at least about 15 mg / m2, at least about 20 mg / m2, at least about 25 mg / m2, at least about 30 mg / m2, at least about 35 mg / m2, at least about 40 mg / m2, at least about 45 mg / m2, at least about 50 mg / m2, at least about 55 mg / m2, at least about 60 mg / m2, at least about 65 mg / m2, at least about 70 mg / m2, at least about 75 mg / m2, at least about 80 mg / m2, at least about 85 mg / m2, at least about 90 mg / m2, at least about 95 mg / m2, at least about 100 mg / m2, at least about 105 mg / m2, at least about 110 mg / m2, at least about 115 mg / m2, at least about 120 mg / m2, at least about 125 mg / m2, at least about 130 mg / m2, at least about 135 mg / m2, at least about 140 mg / m2, at least about 145 mg / m2, or at least about 150 mg / m2, per day. In some embodiments, the Lomustine is administered in an amount of about 50 mg / m2to about 200 mg / m2, about 50 mg / m2to about 150 mg / m2, or about 50 mg / m2to about 110 mg / m2, per day. In some embodiments, the Lomustine is administered in an amount of about 50 mg / m2to about 110 mg / m2, about 60 mg / m2to about 100 mg / m2, or about 70 mg / m2to about 90 mg / m2, per day. In some instances, the Lomustine is administered in an amount of about 60 mg / m2to about 110 mg / m2, per day. In some instances, the Lomustine is administered in an amount of 90 mg / m2, per day. In some instances, the Lomustine is administered in an amount of about 70 mg / m2per day.In some embodiments, the methods of treatment described herein include the administration of the Lomustine once weekly, twice weekly, three times weekly, four times weekly, five times weekly, or six times weekly. In some embodiments, the Lomustine is administered once every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every nine weeks, or every ten weeks. In one example, the Lomustine is administered once every six weeks, for example on days 1, 43 and 85 (e.g., six weeks) of the treatment.In some embodiments, the methods of treatment described herein include the administration of the Lomustine once every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, every eight weeks, every nine weeks, or every ten weeks, in an amount of about 60 mg / m2to about 110 mg / m2, per day.In the methods of treatment described herein, administration of the nitrosourea may cease after a certain period of time. Cessation of nitrosourea administration may coincide with the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) administration. Alternatively, or in addition, cessation of nitrosourea administration may coincide with thecessation of external beam radiotherapy treatment, and / or with the cessation of Temozolomide administration.In some embodiments, the methods of treatment described herein further include the step of administering the nitrosourea during a maintenance period. In embodiments where the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as a monotherapy, “maintenance period” refers to the period in which the patient is not receiving the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). Similarly, in embodiments where the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as a combination therapy, “maintenance period” refers to the period in which the patient is not receiving the combination therapy. As used herein, “maintenance period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of a glioma, for example to keep the patient in progression-free remission for extended periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering one of the therapeutic agents described herein at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria, such as pain, disease manifestation, etc.).In some embodiments, the nitrosourea is administered during the maintenance period after the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) monotherapy. In other embodiments, the nitrosourea is administered during the maintenance period after the cessation of the combination therapy. In some such embodiments, the nitrosourea is administered during the maintenance period immediately following the initial phase of treatment, i.e., immediately following the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In other such embodiments, the nitrosourea is administered during a maintenance period after a treatment break following the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In some instances, a treatment break is about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about eleven weeks, about twelve weeks, about thirteen weeks, about fourteen weeks, about fifteen weeks, about sixteen weeks, about seventeen weeks, or about eighteen weeks from the cessation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In some instances, the cessation of the combination therapy is the cessation of one or more of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) administration, external beam radiotherapy treatment, and / or Temozolomide administration.In one example, the nitrosourea is administered during the maintenance period as a single dose of the nitrosourea. In one example, the nitrosourea is administered during the maintenance period as two or more doses of the nitrosourea. In some embodiments, the nitrosourea is administered during the maintenance period as two, three, four, five, six, seven, eight, or more doses of the nitrosourea. In one example, the nitrosourea is administered during the maintenance period as six doses of the nitrosourea.The amount of the nitrosourea administered during the maintenance period may be the same as the dosage administered during the initial phase of the methods of treatment described herein. Alternatively, the amount of the nitrosourea administered during the maintenance period may differ to the dosage administered during the initial phase of the methods of treatment described herein.In embodiments, the amount of the nitrosourea administered during the maintenance period is 1 mg / m2to 500 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is at least about 10 mg / m2, at least about 15 mg / m2, at least about 20 mg / m2, at least about 25 mg / m2, at least about 30 mg / m2, at least about 35 mg / m2, at least about 40 mg / m2, at least about 45 mg / m2, at least about 50 mg / m2, at least about 55 mg / m2, at least about 60 mg / m2, at least about 65 mg / m2, at least about 70 mg / m2, at least about 75 mg / m2, at least about 80 mg / m2, at least about 85 mg / m2, at least about 90 mg / m2, at least about 95 mg / m2, at least about 100 mg / m2, at least about 105 mg / m2, at least about 110 mg / m2, at least about 115 mg / m2, at least about 120 mg / m2, at least about 125 mg / m2, at least about 130 mg / m2, at least about 135 mg / m2, at least about 140 mg / m2, at least about 145 mg / m2, or at least about 150 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is about 175 mg / m2, at least about 200 mg / m2, at least about 250 mg / m2, or at least about 300 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is less than about 300 mg / m2, less than about 250 mg / m2, less than about 200 mg / m2, less than about 150 mg / m2, less than about 100 mg / m2, less than about 75 mg / m2, less than about 50 mg / m2, or less than about 25 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is about 50 mg / m2, about 75 mg / m2, about 100 mg / m2, about 125 mg / m2, about 150 mg / m2, about 175 mg / m2, about 200 mg / m2, about 250 mg / m2, or about 300 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is about 25 mg / m2and about 300 mg / m2, between about 50 mg / m2and about 250 mg / m2, or between about 50 mg / m2and about 200 mg / m2, per day. In one example, the amount of the nitrosourea administered during the maintenance period is between about 50 mg / m2and about 200 mg / m2, per day. In some such embodiments, thenitrosourea administered during the maintenance period is selected from Lomustine, Carmustine, Fotemustine, or a mixture thereof.In some embodiments, the nitrosourea is Lomustine, administered during the maintenance period in an amount of about 50 mg / m2to about 200 mg / m2, about 50 mg / m2to about 150 mg / m2, or about 50 mg / m2to about 110 mg / m2, per day. For example, the amount of the Lomustine administered during the maintenance period is about 50 mg / m2to about 110 mg / m2, about 60 mg / m2to about 100 mg / m2, or about 70 mg / m2to about 90 mg / m2, per day. For example, the amount of the Lomustine administered during the maintenance period is about 60 mg / m2to about 110 mg / m2, per day. In some embodiments, the Lomustine is administered during the maintenance period at the dose of about 60 mg / m2to about 110 mg / m2per day, every six weeks. In some embodiments, the Lomustine is administered during the maintenance period at the dose of about 60 mg / m2to about 110 mg / m2per day, every six weeks, for several months.In some embodiments, the nitrosourea is administered during the maintenance period for a period of about one, about two, about three, about four, about six, about eight, about 10, about 12, or more, weeks. In some embodiments, the nitrosourea is administered during the maintenance period for a period of between about one and about 12 weeks, between about two and about 12 weeks, between about four and about 12 weeks, or between about six and about 12 weeks. In one example, the nitrosourea is administered during the maintenance period for a period of about one week. In one example, the nitrosourea is administered during the maintenance period for a period of about two weeks. In one example, the nitrosourea is administered during the maintenance period for a period of about three weeks. In one example, the nitrosourea is administered during the maintenance period for a period of about four weeks. In one example, the nitrosourea is administered during the maintenance period for a period of about 12 weeks. In one example, the nitrosourea is administered during the maintenance period for a period of between about one and about 12 weeks. In some embodiments, the maintenance period is at least about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 week, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, 1 year, or about 2 years. In some such embodiments, the nitrosourea administered during the maintenance period is selected from Lomustine, Carmustine, Fotemustine, or a mixture thereof.In some embodiments, the nitrosourea is Lomustine, administered during the maintenance period for a period of at least about one week, at least about two weeks, at least about three weeks, at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about ten weeks, at leastabout eleven weeks, at least about twelve weeks, at least about thirteen weeks, at least about fourteen weeks, at least about fifteen weeks, or at least about sixteen weeks. In some instances, the Lomustine is administered during the maintenance period for a period of at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about ten weeks, at least about eleven weeks, or at least about twelve weeks. In some such embodiments, the nitrosourea administered during the maintenance period is selected from Lomustine, Carmustine, Fotemustine, or a mixture thereof.In some embodiments, the nitrosourea is Lomustine, administered during the maintenance period at a time interval of from one week to ten weeks, from one week to nine weeks, from one week to eight weeks, from one week to seven weeks, from one week to six weeks, from one week to five weeks, from one week to four weeks, from one week to three weeks, from one week to two weeks, or at a time interval of about one week. For example, Lomustine may be administered during the maintenance period at a time interval of about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, or about ten weeks. In some instances, the Lomustine is administered during the maintenance period at a time interval of about three weeks, about four weeks, about five weeks, or about six weeks.In embodiments where the nitrosourea chemotherapy is administered in combination with a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), the methods described herein comprise administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and the nitrosourea chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and the nitrosourea may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the nitrosourea chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), during the same time period as the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), or after the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). Alternatively or in addition, the nitrosourea chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In any such instances, the administration of the nitrosourea chemotherapy and the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In embodiments where the nitrosourea chemotherapy is administered in combination with a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and external beam radiotherapy, the methods described herein comprise administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), external beam radiotherapy and the nitrosourea chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), external beam radiotherapy and the nitrosourea chemotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the nitrosourea chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or external beam radiotherapy, during the same time period as the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or external beam radiotherapy, or after the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or external beam radiotherapy. Alternatively, or in addition, the nitrosourea chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or external beam radiotherapy. In any such instances, the administration of the nitrosourea chemotherapy, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), and / or external beam radiotherapy may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In embodiments where the nitrosourea chemotherapy is administered in combination with a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and Temozolamide chemotherapy, the methods described herein comprise administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy and the nitrosourea chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy and the nitrosourea chemotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the nitrosourea chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or Temozolamide chemotherapy, during the same time period as the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or Temozolamide chemotherapy, or after the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and / or Temozolamide chemotherapy. Alternatively or in addition, the nitrosourea chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and Temozolamidechemotherapy. In any such instances, the administration of the nitrosourea chemotherapy, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), and / or Temozolamide chemotherapy may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In embodiments where the nitrosourea chemotherapy is administered in combination with a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy and external beam radiotherapy, the methods described herein comprise administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, external beam radiotherapy and the nitrosourea chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, external beam radiotherapy and the nitrosourea chemotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the nitrosourea chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, and / or external beam radiotherapy, during the same time period as the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, and / or external beam radiotherapy, or after the commencement of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, and / or external beam radiotherapy. Alternatively or in addition, the nitrosourea chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, and / or external beam radiotherapy. In any such instances, the administration of the nitrosourea chemotherapy, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), Temozolamide chemotherapy, and / or external beam radiotherapy may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In some embodiments, the compound of Formula I is administered, in combination with the nitrosourea chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with the nitrosourea chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I is administered, in combination with the nitrosourea chemotherapy and external beam radiotherapy, as a single dose, on day zero, one,two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with the nitrosourea chemotherapy and external beam radiotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I is administered, in combination with the nitrosourea chemotherapy and Temozolomide chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with the nitrosourea chemotherapy and Temozolomide chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I is administered, in combination with the nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with the nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered, in combination with the nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, as more than one dose at any two or more timepoints (e.g, days from commencement of treatment) throughout the duration of treatment. Similarly, in some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered, in combination with nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, as more than one dose at any two or more timepoints (e.g, days from commencement of treatment) throughout the duration of treatment. In one example, compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a further dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as three substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as four substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as five substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as six substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose, with each dose administered at regular intervals over the treatment period.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy and external beam radiotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq,at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of the compound of Formula I is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4 the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy and external beam radiotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments,the total dose of the compound of Formula I is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of the compound of Formula I is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq andabout 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.External beam radiotherapyExternal beam radiotherapy, also referred to as external radiation therapy (XRT), is a method for delivering a beam, or several beams, of high-energy x-rays targeted to a tumour site.In some embodiments, the methods described herein involve administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with external beam radiotherapy. In some embodiments, the methods described herein involve administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with external beam radiotherapy and a chemotherapy. It has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosoureachemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma. Further, it has been surprisingly found that a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally administered in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, provides an improved method of treating a glioma, such as a glioblastoma.Accordingly, there is provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy. There is also provided a method of treating a glioma comprising the administration of a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In some embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I and a nitrosourea chemotherapy.In some embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine and a nitrosourea chemotherapy.In some other embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with a compound of Formula I, a nitrosourea chemotherapy, and Temozolomide chemotherapy.In some other embodiments, the external beam radiotherapy is administered in an amount sufficient to treat the glioblastoma when administered in combination with 4-L-[131I]iodo-phenylalanine, a nitrosourea chemotherapy, and Temozolomide chemotherapy.The amount of external beam radiotherapy administered is quantified by its ionizing radiation dose, as measured in Gray (Gy). As would be understood by the skilled person, oneGray is defined as the absorption of one joule of radiation energy per kilogram of matter and so represents an absorbed dose of radiation.In some embodiments, the external beam radiotherapy is administered in an amount of at least about 5 Gy, at least about 10 Gy, at least about 20 Gy, at least about 30 Gy, at least about 40 Gy, at least about 50 Gy, at least about 60 Gy, at least about 70 Gy, at least about 80 Gy, at least about 90 Gy, or at least about 100 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In some embodiments, the external beam radiotherapy is administered in an amount of less than about 100 Gy, less than about 90 Gy, less than about 80 Gy, less than about 70 Gy, less than about 60 Gy, less than about 50 Gy, less than about 40 Gy, less than about 30 Gy, less than about 20 Gy, or less than about 10 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In some embodiments, the external beam radiotherapy is administered in an amount of about 5 Gy, about 10 Gy, about 20 Gy, about 30 Gy, about 40 Gy, about 50 Gy, about 60 Gy, about 70 Gy, about 80 Gy, about 90 Gy, or about 100 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In one example, the external beam radiotherapy is administered in an amount of about 60 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In some embodiments, the external beam radiotherapy is administered in an amount of between about 5 Gy and about 100 Gy, between about 10 Gy and about 90 Gy, between about 20 Gy and about 80 Gy, between about 30 Gy and about 70 Gy, or between about 40 Gy and about 60 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In one example, the external beam radiotherapy is administered in an amount of between about 40 Gy and about 70 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In one example, the external beam radiotherapy is administered in an amount of between about 20 Gy and about 60 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In one example, the external beam radiotherapy is administered in an amount of between about 20 Gy and about 40 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein). In one example, the external beam radiotherapy is administered in an amount of between about 30 Gy and about 36 Gy, in total (e.g., in total throughout the duration of the methods of treatment described herein).The methods of treatment described herein may provide for the administration of the external beam radiotherapy in any number of doses (or fractions) and at any suitable time so as to maximise the therapeutic efficacy of the combination treatment. That is, the external beam radiotherapy may be administered in any number of doses (or fractions) at any number of timepoints (e.g., days from commencement of treatment) so as to provide maximal therapeuticefficacy of the treatment. That is, selecting the number of doses (or fractions) of external beam radiotherapy administered, and the particular timepoints of administration of each dose (or fraction) throughout the duration of treatment, may further maximise the therapeutic efficacy of the combination treatments described herein.Accordingly, the methods of treatment described herein may involve the administration of the external beam radiotherapy as a single dose, or alternatively as more than one dose. In one example, the external beam radiotherapy is administered as a single dose. In one example, the external beam radiotherapy is administered as a single dose of between about 40 Gy and about 70 Gy. In one example, the external beam radiotherapy is administered as a single dose of about 60 Gy. In one example, the external beam radiotherapy is administered as a single dose of about 30 to 40 Gy.In one example, the external beam radiotherapy is administered as five, 10, 15, 20, 25, 30, or more, doses (or fractions). Each dose may administer a substantially equal dose of radiation, or may administer a substantially unequal dose of radiation. In one example, the external beam radiotherapy is administered as five, 10, 15, 20, 25, 30, or more, substantially equal doses. In some embodiments, the external beam radiotherapy is administered as 30 substantially equal doses. In one example, the external beam radiotherapy is administered as 30 substantially equal doses of about 2 Gy (i.e., a total dose of external beam radiotherapy of 60 Gy). In one example, the external beam radiotherapy is administered as 20 substantially equal doses of about 3 Gy (i.e., a total dose of external beam radiotherapy of 60 Gy). In one example, the external beam radiotherapy is administered as 10 substantially equal doses of about 6 Gy (i.e., a total dose of external beam radiotherapy of 60 Gy). In one example, the external beam radiotherapy is administered as 5 substantially equal doses (fractions) of about 6 Gy (i.e., a total dose of external beam radiotherapy of 30 Gy). In one example, the external beam radiotherapy is administered as 18 substantially equal doses (fractions) of about 2 Gy (i.e., a total dose of external beam radiotherapy of 36 Gy).The methods of treatment described herein may involve the administration of a single dose of external beam radiotherapy being administered at any time point (e.g., days from commencement of treatment) throughout the duration of treatment. In the instance where administration of external beam radiotherapy does not commence on day one, it will be understood that administration of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine); or any one of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and a nitrosourea; or any one of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), a nitrosourea chemotherapy and Temozolomide chemotherapy, will signify the commencement of the methods of treatment described herein (i.e., day one). In one example, a single dose of external beamradiotherapy is administered between day one and day 126, between day one and day 119, between day one and day 112, between day one and day 105, between day one and day 98, between day one and day 91, between day one and day 84, between day one and day 77, between day one and day 70, between day one and day 63, between day one and day 56, between day one and day 49, between day one and day 42, between day one and day 35, day one and day 28, day one and day 21, day one and day 14, or day one and day seven, from the commencement of the methods of treatment described herein.In one example, a single dose (or fraction) of external beam radiotherapy is administered each day for the duration of the methods of treatment described herein. In instances where more than one dose (or fraction) of external beam radiation is administered, each dose of external beam radiation may be administered at any suitable timepoint throughout the duration of treatment. For example, these multiple doses of external beam radiation may be spaced substantially evenly (i.e., at regular time intervals) throughout the duration of treatment.In one example, the external beam radiation is administered as 10 substantially equal doses spaced substantially evenly throughout the duration of treatment. In one example, the external beam radiation is administered as 20 substantially equal doses spaced substantially evenly throughout the duration of treatment. In one example, the external beam radiation is administered as 30 substantially equal doses spaced substantially evenly throughout the duration of treatment. In one example, the external beam radiation is administered as 30 substantially equal doses of about 2 Gy spaced substantially evenly throughout the duration of treatment.In some embodiments, the methods of treatment described herein include the administration of external beam radiation for a duration of 42 days (e.g., six weeks) from the commencement of treatment. In one example, the external beam radiation is administered in an amount of about 60 Gy for a duration of about 42 days (e.g., six weeks) from commencement of treatment. In one example, the external beam radiation is administered in an amount of about 60 Gy as 30 substantially equal doses spaced substantially evenly throughout a duration of 42 days (e.g., six weeks) from the commencement of treatment. In one example, the external beam radiation is administered in an amount of about 60 Gy as 30 substantially equal doses of about 2 Gy spaced substantially evenly throughout a duration of 42 days (e.g., six weeks) from the commencement of treatment.In some embodiments, the methods of treatment described herein include the administration of external beam radiation for a duration of 42 days (e.g., six weeks) from the commencement of external beam radiation. In one example, the external beam radiation is administered in an amount of about 60 Gy for a duration of about 42 days (e.g., six weeks) from commencement of external beam radiation. In one example, the external beam radiation isadministered in an amount of about 60 Gy as 30 substantially equal doses spaced substantially evenly throughout a duration of 42 days (e.g., six weeks) from the commencement of external beam radiation. In one example, the external beam radiation is administered in an amount of about 60 Gy as 30 substantially equal doses of about 2 Gy spaced substantially evenly throughout a duration of 42 days (e.g., six weeks) from the commencement of external beam radiation.In some embodiments, where the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered in combination with external beam radiotherapy, the methods of treatment described herein include the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) as a first dose prior to commencement of external beam radiotherapy, and at least one subsequent dose after completion (e.g., cessation) of external beam radiotherapy. In one example, the first dose of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is about 4 GBq. In one example, the at least one subsequent dose of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is about 2 GBq.In some embodiments, the methods of treatment described herein include the administration of the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) prior to commencement of external beam radiotherapy. In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered in parallel with external beam radiotherapy. In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered prior to commencement of and after completion (e.g., cessation) of external beam radiotherapy. In other words, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) may be administered sequentially with external beam radiotherapy. In some embodiments, the total dose of compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is between about 0.5 GBq and about 20 GBq, between about 1 GBq and about 18 GBq, between about 2 GBq and about 16 GBq, between about 2 GBq and about 12 GBq, between about 2 GBq and about 10 GBq, between about 2 GBq and about 6 GBq, between about 4 GBq and about 14 GBq, or between about 8 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is between about 2 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) isbetween about 2 GBq and about 8 GBq. In some examples of the methods described herein, the total dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is between about 2 GBq and about 12 GBq, between about 2 GBq and about 10 GBq, between about 2 GBq and about 8 GBq, or between about 2 GBq and about 6 GBq.In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered prior to commencement of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered in parallel or sequentially with external beam radiotherapy within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose.In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered in parallel with external beam radiotherapy. That is, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and external beam radiotherapy may be administered, for example, on the same day or within the same suitable time interval during the treatment period. For example, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) may be administered within some hours after administration of external beam radiotherapy. In such parallel administration, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and external beam radiotherapy may be administered at any suitable time intervals, such as e.g. every 1-10 days, throughout the treatment period. In some embodiments, the one or more doses of thecompound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and external beam radiotherapy are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine). In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and external beam radiotherapy are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the commencement of the methods of treatment described herein.In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered prior to commencement of and / or after completion (e.g., cessation) of external beam radiotherapy. In other words, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) may be administered sequentially with external beam radiotherapy. For example, in some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered after completion (e.g., cessation) of external beam radiotherapy. For example, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) may be administered several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, the one or more doses of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) are administered within one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered after completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered within several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered several minutes, hours, days or weeks (e.g., 0-10 days) prior to commencement of external beam radiotherapy, and a further one or more doses are administered within several minutes, hours, days or weeks (e.g., 0-10 days) after the completion (e.g., cessation) of external beam radiotherapy. In some embodiments, a first dose of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered prior to commencement of external beam radiotherapy, and a further one or more doses are administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks,eight weeks, nine weeks, or ten weeks after the completion (e.g., cessation) of external beam radiotherapy.TemozolomideTemozolomide, sold under the trade names Temodar®, Temodal®, Temcad®, and others, is a front-line therapy for the treatment of glioma, particularly glioblastoma, having the structure:Temozolomide.In some embodiments, the methods described herein involve administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy. In some embodiments, the methods described herein involve administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy, and external beam radiotherapy. It has been surprisingly found that a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy, provides an improved method of treating a glioma, such as a glioblastoma. It has also been surprisingly found that a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), administered in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy, and external beam radiotherapy, provides an improved method of treating a glioma, such as a glioblastoma.Accordingly, there is provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, to a patient in need thereof. There is also provided a method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), optionally in combination with a nitrosourea chemotherapy, external beam radiotherapy, Temozolomide chemotherapy, or combinations thereof, to a patient in need thereof.In some embodiments, the Temozolomide is administered in an amount sufficient to treat the glioma when administered in combination with a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and nitrosourea chemotherapy. Similarly, in some embodiments, the Temozolomide is administered in an amount sufficient to treat the glioma when administered in combination with a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and external beam radiotherapy.The methods of treatment described herein may provide for the administration of the Temozolomide in any number of doses and at any suitable time so as to maximise the therapeutic efficacy of the combination treatment. Typically, the Temozolomide is administered daily throughout the duration of the methods of treatment described herein. In one example, the Temozolomide is administered daily.The Temozolomide may be administered daily for a duration of one day, seven days, 14 days, 21 days, 28 days, 35 days, 42 days, or more, from the commencement of treatment. In one example, the Temozolomide is administered daily for a duration of about 42 days (e.g., six weeks) from the commencement of treatment.In some embodiments, the Temozolomide is administered in an amount of at least about 10 mg / m2, at least about 25 mg / m2, at least about 50 mg / m2, at least about 75 mg / m2, at least about 100 mg / m2, at least about 125 mg / m2, at least about 150 mg / m2, at least about 175 mg / m2, at least about 200 mg / m2, at least about 250 mg / m2, or at least about 300 mg / m2, per day. In some embodiments, the Temozolomide is administered in an amount of less than about 300 mg / m2, less than about 250 mg / m2, less than about 200 mg / m2, less than about 150 mg / m2, less than about 100 mg / m2, less than about 75 mg / m2, less than about 50 mg / m2, or less than about 25 mg / m2, per day. In some embodiments, the Temozolomide is administered in an amount of about 50 mg / m2, about 75 mg / m2, about 100 mg / m2, about 125 mg / m2, about 150 mg / m2, about 175 mg / m2, about 200 mg / m2, about 250 mg / m2, or about 300 mg / m2, per day. In some embodiments, the Temozolomide is administered in an amount of between about 25 mg / m2and about 300 mg / m2, between about 50 mg / m2and about 250 mg / m2, or between about 50 mg / m2and about 200 mg / m2, per day. In one example, the Temozolomide is administered in an amount of between about 50 mg / m2and about 200 mg / m2, per day.In some preferred embodiments, the methods of treatment described herein include the administration of Temozolomide daily for a duration of 42 days (e.g., six weeks) from the commencement of treatment. In one example, the Temozolomide is administered in an amount of between about 75 mg / m2and about 200 mg / m2, per day, for a duration of about 42 days (e.g., six weeks) from commencement of treatment. In one example, the Temozolomide is administeredin an amount of about 75 mg / m2, per day, for a duration of about 42 days (e.g., six weeks) from commencement of treatment.In the methods of treatment described herein, the Temozolomide administration may cease after a certain period of time. In some instances, completion (e.g., cessation) of the Temozolomide administration coincides with the completion (e.g., cessation) of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) administration, the nitrosourea administration, and / or external beam radiotherapy treatment.In one example, the Temozolomide administration is ceased after 42 days (e.g., six weeks) from commencement of treatment. In this instance, the 42 days from commencement of treatment may be referred to as the “initial phase” of treatment. Following completion (e.g., cessation) of Temozolomide administration, an assessment may be made as to whether to provide the patient with a maintenance dose of Temozolomide, and at what particular dose and suitable time (e.g., interval).In some embodiments, the methods of treatment described herein further include the step of administering the Temozolomide during a maintenance period. As described above, in embodiments where the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered as a monotherapy, “maintenance period” refers to the period in which the patient is not receiving the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine). Similarly, in embodiments where the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) is administered as a combination therapy, “maintenance period” refers to the period in which the patient is not receiving the combination therapy. In some instances, the combination therapy comprises a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and / or nitrosourea chemotherapy and / or external beam radiotherapy treatment.In some embodiments, the Temozolomide is administered during the maintenance period after the cessation of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) monotherapy. In other embodiments, the Temozolomide is administered during the maintenance period after the cessation of the combination therapy. In some such embodiments, the Temozolomide is administered during the maintenance period immediately following the initial phase of treatment, i.e., immediately following the cessation of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In one example, the Temozolomide is administered during the maintenance period from about 42 days (e.g., six weeks), from the commencement of treatment (i.e., immediately following the initial phase of treatment). In other such embodiments, the Temozolomide is administered during a maintenance period after a treatment break following the cessation of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In some instances, atreatment break is about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, about ten weeks, about eleven weeks, about twelve weeks, about thirteen weeks, about fourteen weeks, about fifteen weeks, about sixteen weeks, about seventeen weeks, or about eighteen weeks from the cessation of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) monotherapy or the combination therapy. In some instances, the cessation of the combination therapy is the cessation of one or more of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) administration, external beam radiotherapy treatment, and / or nitrosourea administration.In one example, the Temozolomide is administered during the maintenance period as a single dose of the Temozolomide. In one example, the Temozolomide is administered during the maintenance period as two or more doses of the Temozolomide. In some embodiments, the Temozolomide is administered during the maintenance period as two, three, four, five, six, seven, eight, or more doses of the Temozolomide. In one example, the Temozolomide is administered during the maintenance period as six doses of the Temozolomide.The amount of Temozolomide administered during the maintenance period may be the same as the dosage administered during the initial phase of the methods of treatment described herein. Alternatively, the amount of Temozolomide administered during the maintenance period may differ to the dosage administered during the initial phase of the methods of treatment described herein.In embodiments, the amount of Temozolomide administered during the maintenance period is about 50 mg / m2, about 75 mg / m2, about 100 mg / m2, about 125 mg / m2, about 150 mg / m2, about 175 mg / m2, about 200 mg / m2, about 225 mg / m2, or about 250 mg / m2, per day. In one example, the amount of Temozolomide administered during the maintenance period is about 150 mg / m2, per day. In one example, the amount of Temozolomide administered during the maintenance period is about 175 mg / m2, per day. In one example, the amount of Temozolomide administered during the maintenance period is about 200 mg / m2, per day. In one example, the amount of Temozolomide administered during the maintenance period is between about 50 mg / m2and about 300 mg / m2, per day. In one example, the amount of Temozolomide administered during the maintenance period is between about 150 mg / m2and about 200 mg / m2, per day.In some embodiments, Temozolomide is administered during the maintenance period for a period of about one, about two, about three, about four, about six, about eight, about 10, about 12, or more, weeks. In some embodiments, Temozolomide is administered during the maintenance period for a period of between about one and about 12 weeks, between about two and about 12 weeks, between about four and about 12 weeks, or between about six and about 12 weeks. In one example, Temozolomide is administered during the maintenance period for aperiod of about one week. In one example, Temozolomide is administered during the maintenance period for a period of about two weeks. In one example, Temozolomide is administered during the maintenance period for a period of about three weeks. In one example, Temozolomide is administered during the maintenance period for a period of about four weeks. In one example, Temozolomide is administered during the maintenance period for a period of about 12 weeks. In one example, Temozolomide is administered during the maintenance period for a period of between about one and about 12 weeks. In some embodiments, the maintenance period is at least about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 week, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, 1 year, or about 2 years.In some embodiments, the Temozolomide is administered during the maintenance period as about one, about two, about three, about four, about five, about six, about seven, about eight, about nine, or about 10 maintenance cycles. In embodiments, the maintenance cycles are spaced by about 1 to about 42 days.In embodiments where the Temozolomide chemotherapy is administered in combination with a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and nitrosourea chemotherapy, the methods described herein comprise administering the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and Temozolomide chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and Temozolomide chemotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the Temozolomide chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and / or the nitrosourea chemotherapy, during the same time period as the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and / or the nitrosourea chemotherapy, or after the commencement of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and / or the nitrosourea chemotherapy. Alternatively or in addition, the Temozolomide chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine) and / or the nitrosourea chemotherapy. In any such instances, the administration of the Temozolomide chemotherapy, the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), and / or the nitrosourea chemotherapy may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In embodiments where the Temozolomide chemotherapy is administered in combination with a compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and external beam radiotherapy, the methods described herein comprise administering the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy throughout the same treatment period. That is, the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination. For example, the Temozolomide chemotherapy may be administered prior to the commencement of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy, during the same time period as the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy, or after the commencement of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy. Alternatively or in addition, the Temozolomide chemotherapy may be administered after the completion (e.g., cessation) of the administration of the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy. In any such instances, the administration of the Temozolomide chemotherapy, the compound of Formula I (e.g.,4-L-[131I]iodo-phenylalanine), the nitrosourea chemotherapy, and / or external beam radiotherapy may be separated by a treatment break, which will still be considered to qualify as being administered in combination.In some embodiments, the compound of Formula I is administered, in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I is administered, in combination with nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the 4-L-[131I]iodo-phenylalanine is administered, in combination with nitrosourea chemotherapy, Temozolomide chemotherapy and external beam radiotherapy, as a single dose, on day zero, one, two, three, four, five, six, seven, or more, from commencement of the methods of treatment described herein.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered, in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, as more than one dose at any two or more timepoints (e.g, days from commencement of treatment) throughout the duration of treatment. Similarly, in some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered, in combination with nitrosourea chemotherapy, external beam radiotherapy, and Temozolomide chemotherapy, as more than one dose at any two or more timepoints (e.g, days from commencement of treatment) throughout the duration of treatment. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a further dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as more than one dose, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as three substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as four substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as five substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as sixsubstantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as multiple substantially equal doses, and the first dose is administered on day one from commencement of the methods of treatment described herein, and a final dose is administered within about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks of the first dose, with each dose administered at regular intervals over the treatment period.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of the compound of Formula I is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of the compound of Formula I, administered in combination with nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about 16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of the compound of Formula I is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 18 GBq. In one example, the total dose of the compound of Formula I is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of the compound of Formula I is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine, administered in combination with nitrosourea chemotherapy, external beam radiotherapy and Temozolomide chemotherapy, is at least about 1 GBq, at least about 2 GBq, at least about 3 GBq, at least about 4 GBq, at least about 5 GBq, at least about 6 GBq, at least about 7 GBq, at least about 8 GBq, at least about 9 GBq, at least about 10 GBq, at least about 11 GBq, at least about 12 GBq, at least about 13 GBq, at least about 14 GBq, at least about 15 GBq, at least about 15 GBq, at least about16 GBq, at least about 17 GBq, at least about 18 GBq, at least about 19 GBq, or at least about 20 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 0.5 GBq and about 20 GBq, between about 1.0 GBq and about 18 GBq, between about 2.0 GBq and about 16 GBq, between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 6.0 GBq, between about 4.0 GBq and about 14 GBq, or between about 8.0 GBq and about 12 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 18 GBq. In one example, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 8.0 GBq. In some embodiments, the total dose of 4-L-[131I]iodo-phenylalanine is between about 2.0 GBq and about 12 GBq, between about 2.0 GBq and about 10 GBq, between about 2.0 GBq and about 8.0 GBq, or between about 2.0 GBq and about 6.0 GBq.Treatment RegimenThe methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine). In embodiments, the methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy. That is, in some embodiments, the methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy. In some other embodiments, the methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and external beam radiotherapy. In some other embodiments, the methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy and Temozolomide chemotherapy. In some other embodiments, the methods of treatment described herein comprise administering a therapeutically effective amount of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in combination with a nitrosourea chemotherapy, Temozolomide chemotherapy, and external beam radiotherapy.The phrase “in combination with” will be taken to mean that the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), a nitrosourea chemotherapy, and / or Temozolomide chemotherapy and / or external beam radiotherapy, are administered to the patient throughout the same treatment period.Throughout administration, it is not necessary for each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), a nitrosourea chemotherapy, and / or Temozolomide chemotherapy and / or external beam radiotherapy, to be co-administered or simultaneously administered, at the same point in time (e.g., within the same day / hour / minute), to the patient. Accordingly, in one example, the method described herein comprises administering the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), a nitrosourea chemotherapy, and / or Temozolomide chemotherapy and / or external beam radiotherapy throughout the same treatment period. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), a nitrosourea chemotherapy, and / or Temozolomide and / or external beam radiotherapy may each be administered at any suitable time (e.g., interval) throughout the same treatment period, which will be considered to qualify as being administered in combination.The treatment period will be considered to commence upon the administration of any one of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or Temozolomide chemotherapy and / or external beam radiotherapy. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered on day one of treatment, and may signify the commencement of the treatment period. In one example, nitrosourea chemotherapy is administered on day one of treatment, and may signify the commencement of the treatment period. In one example, external beam radiotherapy is administered on day one of treatment, and may signify the commencement of the treatment period. In one example, Temozolomide chemotherapy is administered on day one of treatment, and may signify the commencement of the treatment period.The treatment period may be any suitable duration, as determined by the person skilled in the art, so as to treat the glioma, including glioblastoma. In some embodiments, the treatment period is between about one and about 52 weeks, between about one and about 36 weeks, between about one and about 24 weeks, between about one and about 24 weeks, between about one and about 12 weeks, or between about one and about six weeks in duration. In some embodiments, the treatment period is at least about one week, at least about two weeks, at least about four weeks, at least about six weeks, at least about 12 weeks, at least about 24 weeks, at least about 36 weeks, or at least about 48 weeks in duration. In some embodiments, the treatment period is less than about 52 weeks, less than about 48 weeks, less than about 36 weeks, less than about 24 weeks, less than about 12 weeks, or less than about six weeks in duration. In one example, the treatment period is about six weeks in duration.In one example, the treatment period further comprises a maintenance period. The maintenance period may be any suitable duration, as determined by the person skilled in the art, so as to maintain treatment of the glioblastoma. In some embodiments, the maintenance periodis between about one and about 52 weeks, between about one and about 36 weeks, between about one and about 24 weeks, between about one and about 24 weeks, between about one and about 12 weeks, or between about one and about six weeks in duration. In some embodiments, the maintenance period is at least about one week, at least about two weeks, at least about four weeks, at least about six weeks, at least about 12 weeks, at least about 24 weeks, at least about 36 weeks, or at least about 48 weeks in duration. In some embodiments, the maintenance period is less than about 52 weeks, less than about 48 weeks, less than about 36 weeks, less than about 24 weeks, less than about 12 weeks, or less than about six weeks in duration. In one example, the maintenance period is about 12 weeks in duration.In one example, the maintenance period commences immediately after the completion (e.g., cessation) of the treatment period. In one example, the methods of treatment described herein comprise an initial treatment period of about six weeks in duration, followed immediately by a maintenance period of about 12 weeks in duration.In some embodiments, any one of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and / or Temozolomide chemotherapy and / or external beam radiotherapy is commenced on day one of the treatment period. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is commenced on day one of the treatment period. In one example, nitrosourea chemotherapy is commenced on day one of the treatment period. In one example, external beam radiotherapy is commenced on day one of the treatment period. In one example, Temozolomide chemotherapy is commenced on day one of the treatment period. In some embodiments, any combination of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy is commenced on day one of the treatment period. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and nitrosourea chemotherapy are each commenced on day one of the treatment period. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and nitrosourea chemotherapy and external beam radiotherapy are each commenced on day one of the treatment period. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) and nitrosourea chemotherapy and Temozolomide chemotherapy are each commenced on day one of the treatment period. In one example, the compound of Formula I (e.g., 4-L-[131I] iodo-phenylalanine) and nitrosourea chemotherapy and Temozolomide chemotherapy and external beam radiotherapy are each commenced on day one of the treatment period.Following commencement of the treatment period, each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or Temozolomide chemotherapy, and / or external beam radiotherapy may be administered to the patient at anysuitable time (e.g., interval) for the duration of the treatment period as determined by the person skilled in the art. In one example, each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and / or external beam radiotherapy and / or Temozolomide chemotherapy are administered to the patient on the same day(s) of the treatment period. In one example, each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy are administered to the patient on different (e.g., staggered) day(s) of the treatment period. Purely by way of example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered on day one, and nitrosourea chemotherapy may be administered on day two of the treatment period. Similarly, and purely by way of example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may be administered on day one, the nitrosourea chemotherapy may be administered on day two, and external beam radiotherapy and / or Temozolomide chemotherapy may be administered on day three of the treatment period.The pattern of administration of each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy, being the interval dosing regimen, may remain consistent throughout the treatment period. For example, administration of each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy may occur every one, two, three, four, five, six, seven, or more days throughout the treatment period for the duration of treatment. Alternatively, the pattern of administration of each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy, being the interval dosing regimen, may be varied throughout the treatment period (e.g., irregular dosing intervals).Just as it is not necessary for the administration of each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy, and / or external beam radiotherapy and / or Temozolomide chemotherapy to commence on the same day of the treatment period, it is not necessary for the administration of each of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), nitrosourea chemotherapy and / or external beam radiotherapy and / or Temozolomide chemotherapy to conclude on the same day of the treatment period. Purely by way of example, administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may conclude during week 4 of the treatment period, and administration of the nitrosourea chemotherapy may conclude during week 5 of the treatment period. Similarly, and purely by way of example, administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) may conclude during week 4 of the treatment period, administration of thenitrosourea chemotherapy may conclude during week 5 of the treatment period, and administration of the external beam radiotherapy and / or Temozolomide chemotherapy may conclude during week 6 of the treatment period. Regardless, such treatment will be considered as being in combination throughout the treatment period.Patient PopulationThe methods of treatment described herein may be administered to a patient that has been diagnosed with glioma, including glioblastoma, through any conventional means as would be understood by the person skilled in the art. For example, the patient may have been diagnosed with glioblastoma through any one or more of a computed tomography (CT) scan, a magnetic resonance imaging (MRI) scan, or tissue biopsy. In one example, the patient has been diagnosed with glioblastoma through a CT scan. In one example, the patient has been diagnosed with glioblastoma through an MRI scan. In one example, the patient has been diagnosed with glioblastoma through a tissue biopsy.The methods of treatment described herein may be administered to a patient suffering from any form of glioblastoma (e.g., primary or secondary). Primary glioblastoma is the most common form of glioblastoma, and is also acknowledged as the most aggressive form. In one example, the method of treatment described herein is administered to a patient suffering from primary glioblastoma. Secondary glioblastoma is a less common form of glioblastoma, and is less aggressive due to its understood origination from lower-grade, less aggressive astrocytoma. In one example, the method of treatment described herein is administered to a patient suffering from secondary glioblastoma.The glioblastoma may be diagnosed as being located in any area of the patient’s brain. That is, a glioblastoma may form in any lobe of the brain, most commonly the frontal lobe and temporal lobe, though even the brain stem and cerebellum. Similarly, the glioblastoma may not be localized to one particular area of the brain, and may instead be observed throughout two or more areas of the brain. In one example, the method of treatment described herein is administered to a patient diagnosed with glioblastoma primarily in the frontal lobe of the brain. In one example, the method of treatment described herein is administered to a patient diagnosed with glioblastoma primarily in the temporal lobe of the brain. In one example, the method of treatment described herein is administered to a patient diagnosed with glioblastoma primarily in the brain stem. In one example, the method of treatment described herein is administered to a patient diagnosed with glioblastoma primarily in the cerebellum. In one example, the method of treatment described herein is administered to a patient diagnosed with glioblastoma that is not primarily localized in the infratentorial compartment.The diagnosed glioblastoma may be one tumour, or may instead be more than one tumour located within the brain and / or body. Where the glioblastoma is more than one tumour, it is understood that the distant tumour lesions are likely to have originated from the primary glioblastoma tumour. Such distant tumour lesions may be referred to as multifocal distant recurrence tumour lesions. In one example, the method of treatment described herein is administered to a patient that does not have multifocal distant recurrence tumour lesions.The methods of treatment described herein may be administered to a patient of any particular age. In one example, the method of treatment described herein is administered to an adult patient (i.e., a patient of at least (>) 18 years of age). For example, the patient may be at least 18, at least 30, at least 40, at least 50, at least 60, at least 70, or at least 80 years of age. In one example, the patient is at least 18 years of age. In one example, the method of treatment described herein is administered to a non-adult patient (i.e., a patient less than (<) 18 years of age). In one example, the patient is less than 18 years of age. In one example, the method of treatment described herein is administered to a paediatric patient (i.e., a patient of less than (<) 12 years of age). In one example, the patient is less than 12 years of age.The methods of treatment described herein may be administered to a male or female patient. In one example, the method of treatment described herein is administered to a male patient. In one example, the method of treatment described herein is administered to a female patient.In embodiments, the methods of treatment described herein are intended to be administered to patients that have undergone prior surgical resection of the glioblastoma tumour. As would be understood by the person skilled in the art, surgical resection of the glioblastoma is a front-line treatment that involves the surgical removal (decompression) of the tumour. In one example, the method of treatment described herein is administered to a patient that has undergone surgical resection of the glioblastoma tumor. In one example, the method of treatment described herein is administered to a patient that has undergone maximal surgical resection of the glioblastoma tumor.However, even maximal surgical resection is often unable to completely remove the glioblastoma tumour with any suitable margins from the brain tissue, meaning glioblastoma tumour cells will remain in the patient’s brain. Due to this, following maximal surgical resection of the glioblastoma tumour, subsequent chemotherapy and / or radiotherapy is additionally required.Accordingly, the methods of treatment described herein may be commenced at any desirable time following maximal surgical resection of the glioblastoma. In one example, the methods of treatment described herein are commenced immediately following maximal surgicalresection of the glioblastoma. Alternatively, there may be a period of delay following maximal surgical resection prior to the methods of treatment described herein being commenced. This may allow, for example, for a patient to recover from the surgery. This period of delay may be, for example, one day, seven days, 10 days, 14 days (i.e., two weeks), 21 days (i.e., three weeks), 28 days (i.e., four week), 35 days (i.e., five weeks), 42 days (i.e., six weeks), 49 days (i.e., seven weeks), 56 days (i.e., eight weeks), 63 days (i.e., nine weeks), 70 days (i.e., 10 weeks), or more. In one example, the methods of treatment described herein are commenced within about 42 days following maximal surgical resection of the glioblastoma. In one example, the methods of treatment described herein are commenced within about 35 days following maximal surgical resection of the glioblastoma. In one example, the methods of treatment described herein are commenced within about 28 days following maximal surgical resection of the glioblastoma. In one example, the methods of treatment described herein are commenced within about 21 days following maximal surgical resection of the glioblastoma. In one example, the methods of treatment described herein are commenced within about 14 days following maximal surgical resection of the glioblastoma. Similarly, the period of delay may be, for example, between about one day and about 70 days, between about seven days and about 56 days, or between about 14 days and about 42 days. In one example, the methods of treatment described herein commence within about 14 days to about 42 days following maximal surgical resection of the glioblastoma.The methods of treatment described herein may be administered to a patient that has not received prior chemotherapy for the diagnosed glioma, including glioblastoma. In this instance, the patient may have previously received chemotherapy for another medical reason, including the treatment of a cancerous tumour, but not for the currently specifically diagnosed glioblastoma. That is, the patient has not previously received chemotherapeutics for the treatment of the currently specifically diagnosed glioblastoma. In one example, the method of treatment described herein is administered to a patient that has not received prior chemotherapy for the currently specifically diagnosed glioblastoma. Such prior chemotherapeutic treatment may include any chemotherapeutic indicated in the treatment of glioblastoma such as, for example, Temozolomide, Carmustine, Bevacizumab, and Lomustine. In one example, the patient has not previously received prior chemotherapy being Temozolomide. In one example, the patient has not previously received prior chemotherapy being Carmustine. In one example, the patient has not previously received prior chemotherapy being Bevacizumab. In one example, the patient has not previously received prior chemotherapy being Lomustine.Similarly, the methods of treatment described herein may be administered to a patient that has not received prior radiotherapy for the currently specifically diagnosed glioblastoma. In this instance, the patient may have previously received radiotherapy for another medical reason,including the treatment of a cancerous tumour, but not for this currently specifically diagnosed glioblastoma. That is, the patient has not previously received radiotherapy for the treatment of the currently specifically diagnosed glioblastoma. In one example, the method of treatment described herein is administered to a patient that has not received prior radiotherapy for the currently specifically diagnosed glioblastoma.EfficacyAs would be understood by the person skilled in the art, numerous adverse events, or side effects, may be observed during treatment of various cancers with chemotherapy and / or radiotherapy. These side effects are typically due to systemic toxicity such as hematologic toxicity, neurological toxicity, cardiotoxicity, hepatotoxicity, nephrotoxicity, ototoxicity, and gastrointestinal toxicity. Such side effects include, but are not limited to, diarrhoea, myelosuppression, neutropenia, neutropenic fever, neutropenic infection, leukopenia, thrombocytopenia, lymphopenia, hypersensitivity, renal impairment, renal failure, pulmonary toxicity (dyspnea, cough, pneumonia, interstitial lung disease), teratogenicity, nausea, vomiting, dehydration, abdominal pain, septic shock, constipation, anorexia, mucositis, anemia, asthenia, pain, fever, infection, dizziness, somnolence, confusion, vasodilatation, hypotension, thromboembolic events, abnormal bilirubin, rash, alopecia, and decreasing body weight.The methods of treatment described herein may provide for a reduction in one or more adverse events in comparison to the administration of external beam radiotherapy and / or Temozolomide chemotherapy alone.The toxicity of a drug refers to the degree to which damage is caused to the organism and is measured by its effect off-target. In oncology, one such measurement of toxicity in animal models is weight loss, which can determine the maximum tolerated dose (MTD). In humans, toxicity is commonly determined by specified adverse events (AE), which typically identify the dose limiting toxicity. It will be appreciated that usually in oncology, there is a narrow therapeutic window and off-target toxicities are considered a normal side effect of killing tumour cells. In some embodiments, the methods of treatment described herein provide for a reduction in toxicity in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy. In some embodiments, the methods of treatment described herein provide for a reduction in toxicity, as measured by the number of patients in which a specific adverse event is observed, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy.In some embodiments, the methods of treatment described herein provide for a reduction in an observed adverse event of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In some embodiments, the methods of treatment described herein provide for a reduction in the severity of an observed adverse event in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in an observed adverse event of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in an observed adverse event of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, wherein the adverse event is selected from the group consisting of diarrhoea, myelosuppression, neutropenia, neutropenic fever, neutropenic infection, leukopenia, thrombocytopenia, lymphopenia, hypersensitivity, renal impairment, renal failure, pulmonary toxicity (dyspnea, cough, pneumonia, interstitial lung disease), teratogenicity, nausea, vomiting, dehydration, abdominal pain, septic shock, constipation, anorexia, mucositis, anemia, asthenia, pain, fever, infection, dizziness, somnolence, confusion, vasodilatation, hypotension, thromboembolic events, abnormal bilirubin, rash, alopecia, and decreasing body weight.In one example, the methods of treatment described herein provide for a reduction in the severity of an observed adverse event in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, wherein the adverse event is selected from the group consisting of diarrhea, myelosuppression, neutropenia, neutropenic fever, neutropenic infection, leukopenia, thrombocytopenia, lymphopenia, hypersensitivity, renal impairment, renal failure, pulmonary toxicity (dyspnea, cough, pneumonia, interstitial lung disease), teratogenicity, nausea, vomiting, dehydration, abdominal pain, septic shock, constipation, anorexia, mucositis, anemia, asthenia, pain, fever, infection, dizziness, somnolence, confusion, vasodilatation,hypotension, thromboembolic events, abnormal bilirubin, rash, alopecia, and decreasing body weight.In one example, the methods of treatment described herein provide for a reduction in an observed adverse event of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, wherein the adverse event is selected from the group consisting of haematological toxicity, inflammation-induced intracranial hypertension, fatigue, thrombocytopenia, weight loss, diarrhea, and headache.In one example, the methods of treatment described herein provide for a reduction in the severity of an observed adverse event in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, wherein the adverse event is selected from the group consisting of haematological toxicity, inflammation-induced intracranial hypertension, fatigue, thrombocytopenia, weight loss, diarrhea, and headache.In one example, the methods of treatment described herein provide for a reduction in haematological toxicity in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in haematological toxicity of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in inflammation-induced intracranial hypertension in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in inflammation-induced intracranial hypertension of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in fatigue in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in fatigue of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in thrombocytopenia in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in thrombocytopenia of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in weight loss in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in weight loss of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in diarrhea in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in diarrhea of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, incomparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In one example, the methods of treatment described herein provide for a reduction in headache severity and / or incidence in at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, of the patient population, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In one example, the methods of treatment described herein provide for a reduction in headache of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, in comparison to the administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.In some embodiments, the methods of treatment described herein provide enhanced clinical efficacy in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts. In some embodiments, the methods of treatment described herein provide an improved efficacy property selected from the group consisting of progression free survival, time to progression, objective response rate (PR + CR), overall response rate, overall survival, and duration of response, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts.As would be understood by the person skilled in the art, both progression free survival and overall survival may be measured at any suitable end -point. In some embodiments, progression free survival is measured at 10 months, 12 months, 18 months, 24 months, 36 months, 48 months, or 60 months, following commencement of the methods of treatment described herein. Similarly, in some embodiments, overall survival is measured at 10 months, 12 months, 18 months, 24 months, 36 months, 48 months, or 60 months, following commencement of the methods of treatment described herein.In some embodiments, the methods of treatment described herein provide for an increase in progression free survival of the patient in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone. In some embodiments, the methods of treatment described herein provide for an increase in progression free survival of the patient by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone. In some embodiments, the methods of treatment described herein provide for an increase in progression free survival ofthe patient by at least one month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, or 24 months, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone. In some embodiments, the methods of treatment described herein provide for an increase in progression free survival of the patient in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy when measured at 12 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in progression free survival of the patient by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts, when measured at 12 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in progression free survival of the patient by at least at least one month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, or 24 months, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy, in substantially equivalent amounts, when measured at 12 months following commencement of the methods of treatment described herein.In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least one month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34months, 35 months, or 36 months in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone.In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 12 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 12 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least one month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, or 36 months, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 12 months following commencement of the methods of treatment described herein.In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 24 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 24 months following commencement of the methods of treatment described herein. In some embodiments, the methods of treatment described herein provide for an increase in overall survival of the patient by at least one month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, or 36 months, in comparison to administration of nitrosourea chemotherapy, and / or external beam radiotherapy, and / or Temozolomide chemotherapy alone, in substantially equivalent amounts, when measured at 24 months following commencement of the methods of treatment described herein.CompositionsThe methods of treatment described herein involve the administration of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) in any suitable formulation or composition. That is, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered to a subject in the form of a suitable formulation or composition. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as a composition. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is administered as a pharmaceutical composition.Accordingly, the present disclosure also provides pharmaceutical formulations or compositions comprising the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. Other pharmaceutical excipients and / or additives suitable for use in the compositions according to the present disclosure are listed in "Remington: The Science & Practice of Pharmacy", 19. sup. th ed., Williams & Williams, (1995), and in the "Physician's Desk Reference", 52. sup. nd ed., Medical Economics, Montvale, N.J. (1998), and in "Handbook of Pharmaceutical Excipients", Third Ed., Ed. A. H. Kibbe, Pharmaceutical Press, 2000.The compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) of the present disclosure may be formulated in compositions including those suitable for intranasal delivery, inhalation to the lung, by aerosol, or parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by bringing the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) into association with a liquid carrier to form a solution or a suspension, or alternatively, bring the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) intoassociation with formulation components suitable for forming a solid, optionally a particulate product, and then, if warranted, shaping the product into a desired delivery form.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for parenteral delivery. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for intravenous administration. For example, in one embodiment, the formulation may be a sterile, lyophilized composition that is suitable for reconstitution in an aqueous vehicle prior to injection (e.g., intravenous administration).In some embodiments, a formulation suitable for parenteral administration conveniently comprises a sterile aqueous preparation of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), which may for example be formulated to be isotonic with the blood of the recipient. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated in a buffered solution. As would be understood by the person skilled in the art, a buffered solution is employed to maintain pH at a largely consistent value such that it resists changes to pH upon exposure to strongly acidic and / or strongly basic environments. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated in a buffered solution for injection. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated in a buffered solution for a single intravenous use. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for intravenous administration via an automated infusion system.In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises any one or more of ascorbic acid, sodium ascorbate, and ethanol. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises ascorbic acid. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises sodium ascorbate. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises ethanol. The formulation may be provided as a lyophilized powdered form for reconstitution in sterile water for injection. Alternatively, the formulation may be provided already reconstituted in sterile water for injection. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises sterile water for injection. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) formulation comprises any one or more of ascorbic acid, sodium ascorbate, ethanol, and water for injection.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is provided as a 25 mL solution. In some embodiments, the compound of Formula I(e.g., 4-L-[131I]iodo-phenylalanine) composition is provided as a 25 mL buffered solution. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition comprises at least about 2 mg, at least about 4 mg, at least about 6 mg, at least about 7 mg, at least about 8 mg, at least about 9 mg, at least about 10 mg, at least about 11 mg, at least about 12 mg, at least about 14 mg, at least about 16 mg, at least about 18 mg, or at last about 20 mg of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition per 25 mL solution. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition comprises an amount of between about 4 mg and about 16 mg of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) per 25 mL solution. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition comprises an amount of between about 8 mg and about 12 mg of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) per 25 mL solution.In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is provided as a solution for injection, wherein each 25 mL of solution comprises between about 8 mg and about 12 mg of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), ascorbic acid, sodium ascorbate, ethanol, and water for injection. In one example, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) is provided as a solution for injection, wherein each 25 mL of solution comprises between about 8 mg and about 12 mg of the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine), 272.5 mg ascorbic acid, 817.5 mg sodium ascorbate, about 2.8 mL ethanol, and water for injection.In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for co-administration with a nitrosourea. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for coadministration with Lomustine. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for co-administration with Carmustine. In some embodiments, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition is formulated for co-administration with Fotemustine. In such instances, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition may be formulated for sequential co-administration with a nitrosourea or may alternatively be formulated for simultaneous co-administration with a nitrosourea (i.e., 4-L-[131I]iodo-phenylalanine and a nitrosourea are formulated in the same composition for single administration). Similarly, the compound of Formula I (e.g., 4-L-[131I]iodo-phenylalanine) composition may be formulated for sequential co-administration with Temozolomide or may alternatively be formulated for simultaneous co-administration with Temozolomide (i.e., 4-L-[131I]iodo-phenylalanine and Temozolomide are formulated in the same composition for single administration). In some embodiments, anitrosourea and Temozolomide may be formulated in the same composition for single administration. For example, Lomustine and Temozolomide may be formulated in the same composition for single administration, e.g. oral administration.The present disclosure will now be described with reference to the following examples which illustrate some particular aspects of the present disclosure. However, it is to be understood that the particularity of the following description of the present disclosure is not to supersede the generality of the preceding description of the present disclosure.EXAMPLESExample 1: Clinical Study of 4-L-r131I1iodo-phenylalanine as Monotherapy or in Combination with Lomustine Chemotherapy in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence.Study TitleA Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of lodofalan (131I) Solution for Injection (TLXlOl-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IP AX-3).Rationale for Study DesignPatients diagnosed with glioblastoma have limited options for treatment. The initial course of treatment includes maximal safe debulking surgery, followed by external beam radiation therapy (60 Gy) in combination with Temozolomide over the course of 6 weeks, followed by maintenance treatment with Temozolomide for 6 cycles and optional tumor-treating fields (TTFields) until first progression.This clinical study aims to evaluate the benefits and risks of 4-L-[131I]iodo-phenylalanine (also referred to as TLXlOl-Tx,131I-IPA-TLX- 101,131I-IPA, [131I]IPA or iodofan (131I)) concomitant with Lomustine (or 4-L-[131I]iodo-phenylalanine alone) compared to Lomustine alone in patients with radiographically confirmed recurrent glioblastoma at first recurrence.This open-label, pivotal study consists of two parts: Part 1 is “Safety and Dosimetry Lead-In " to establish the maximum tolerated dose (MTD) to inform the recommended dose for the randomized treatment expansion (see Part 2), safety, tolerability, dosimetry, and preliminary efficacy of 4-L-[131I]iodo-phenylalanine concomitant with Lomustine and determine absorbed radiation doses to the tumor and bone marrow. Part 2 is a “Randomized Study” to assess theefficacy of 4-L-[131I]iodo-phenylalanine in combination with Lomustine on overall survival (OS) compared to Lomustine monotherapy.Part 1 is implemented using a Bayesian Optimization Interval (BOIN) model. Upon successful completion and the determination of the recommended dose combination of 4-L-[131I]iodo-phenylalanine and Lomustine (or single agent 4-L-[131I]iodo-phenylalanine) with 6 participants at dose level, the dose expansion cohort opens for recruitment of approximately 12 participants. The collective data from BOIN and the dose expansion cohort is reviewed with the FDA before Part 2 opens for accrual. Modifications to Part 2 are incorporated based on findings from Part 1.4-L-[131I]Iodo-phenylalanine is transported into glioma cells via large neutral amino acid transporter 1 (LAT-1), which is the same molecular uptake mechanism as [18F]FET. Thus, [18F]FET PET can be used to verify tumor expression of LAT-1 prior to treatment as well as to assess response to 4-L-[131I]iodo-phenylalanine.Study Objectives and EndpointsObjectives EndpointsPrimaryPart 1 Safety and Dosimetry Lead-InPart la BOIN: Part la BOIN:Dose optimization and determine the Assessment of TEAEs type as described as doseRP3D. limiting, frequency, severity according to NCI To determine the MTD and CTCAE v5.0recommended dose of 4-L-[131I]iodo- phenylalanine plus Lomustine (or 4-L- [131I]iodo-phenylalanine as amonotherapy) for the safety doseexpansion Part lb.Part lb Dose Expansion Cohort: Part lb Dose Expansion Cohort:To determine the safety, tolerability, and Safety assessments include: physical examination, the recommended Phase 3 study dose of vital signs, clinical laboratory assessments, 4-L-[131I]iodo-phenylalanine in adverse events reported according to the NCI combination with Lomustine (or 4-L- CTCAE v5.0. Tolerability as assessed by Health- [131I]iodo-phenylalanine as a Related Quality of Life (HRQoL) total scores on monotherapy) in participants with European Organization for Research and confirmed first recurrence of Treatment of Cancer - EORTC QLQ-C30 and glioblastoma. EORTC-BN20 questionnaires, neurological symptoms assessed with the NANO scale.Part 2 Randomized StudyTo evaluate whether 4-L-[131I]iodo- OS determined from the date of randomization phenylalanine concomitant with until death from any cause.Lomustine (or 4-L-[131I]iodo- phenylalanine monotherapy based on thetotality of data from Part 1) improvesoverall survival (OS) compared toLomustine alone.SecondaryPart 1 Safety and Dosimetry Lead-InPart la and lb: Part la and lb:To determine tumor and normal organ Absorbed radiation doses based on quantitative radiation dosimetry for 4-L-[131I]iodo- imaging (expressed as mGy / MBq of administered phenylalanine in confirmed recurrent 4-L-[131I]iodo-phenylalanine) to tumor and bone glioblastoma participants. marrow, using Single-Photon Emission Computed Tomography (SPECT) imaging. The planar images of the head and tumor volume estimates from CT / MRI are used to obtain an estimate of the tumor dose per administered activity of131I.Part la and lb: Part la and lb:To characterize the PK and the urinary Time course of the radioactivity and of 4-L-excretion of 4-L-[131I]iodo-phenylalanine. [131I]iodo-phenylalanine in blood and cumulative urine excretion of the radioactivity after administration of 4-L-[131I]iodo-phenylalanine. Blood and urine PK parameters of 4-L-[131I]iodo- phenylalanine, PK / PD modeling is performed using venous blood samples and if data allows, exposure-response analyses is performed to correlate blood PK.Part la BOIN: Part la BOIN:To determine the safety and tolerability of Safety assessments include physical examination, 4-L-[131I]iodo-phenylalanine in vital signs, ECG abnormalities, clinical laboratory combination with Lomustine (or 4-L- assessments, adverse events reported according to [131I]iodo-phenylalanine as a the NCI CTCAE v5.0. Tolerability as assessed by monotherapy) in patients with confirmed HRQoL total scores on European Organization for first recurrence of glioblastoma. Research and Treatment of Cancer - EORTC QLQ-C30 and EORTC-BN20 questionnaires, neurological symptoms assessed with the NANO scale.Part lb Dose Expansion Cohort: Part lb Dose Expansion Cohort:To determine preliminary efficacy for the Progression-free survival (PFS) from the time of MTD treatment regimen. enrollment as assessed by central core lab using RANG 2.0 or death due to any cause (whichever occurs first).Part lb Dose Expansion Cohort: Part lb Dose Expansion Cohort:To determine preliminary efficacy for the PFS from enrollment assessed by central core lab MTD treatment regimen based on tumor using PET RANG 1.0 or death due to any cause, metabolic changes. (whichever occurs first)Part lb Dose Expansion Cohort: Part lb Dose Expansion Cohort:To determine the response rate at the Objective response rate assessed by the central core MTD. lab according to RANG 2.0.Part 2 Randomized StudyTo evaluate whether 4-L-[131I]iodo- PFS from the date of randomization per RANG 2.0 phenylalanine concomitant with criteria as assessed by the central core lab or death Lomustine (or as 4-L-[131I]iodo- due to any cause (whichever occurs first). phenylalanine monotherapy) improvesPFS of participants compared toLomustine alone.To evaluate whether 4-L-[131I]iodo- PFS from the date of enrollment per PET RANG phenylalanine concomitant with 1.0 criteria as assessed by the central core lab or Lomustine (or as 4-L-[131I]iodo- death due to any cause (whichever occurs first). phenylalanine monotherapy) improvesPFS as determined by [18F]FET-PETimaging of patients compared toLomustine alone.To assess Health Related Quality of Life Tolerability as assessed by Health-Related Quality of participants treated with 4-L-[131I]iodo- of Life (HRQoL) total scores on European phenylalanine plus Lomustine or 4-L- Organization for Research and Treatment of

[1311] iodo-pheny lalanine monotherapy . Cancer - EORTC QLQ-C30 and EGRTC-BN20 questionnaires, NANO.To assess the safety and tolerability. Safety assessments include physical examination, vital signs, and clinical laboratory assessments as well as adverse events reported according to the NCI CTCAE v5.0.Study design and summaryThis is a multinational, multicenter, prospective, controlled, open-label pivotal study. This pivotal study assesses the benefits and risks of 4-L-[131I]iodo-phenylalanine concomitant with Lomustine (or 4-L-[131I]iodo-phenylalanine alone) compared to Lomustine alone in participants with radiographically confirmed recurrent glioblastoma at first recurrence.This study consists of two parts:• Part 1: Safety and Dosimetry Lead-In• Part 2: Randomized StudyRecommendations from the BOIN suite in Part 1 are utilized to make decisions regarding the dose for the dose-expansion cohort and the subsequent evaluation in Part 2. Overview of Part 1 and Part 2 is shown in Fig. 1.Part 1: Safety and Dosimetry Lead-InPart 1 assesses the safety and tolerability of 4-L-[131I]iodo-phenylalanine monotherapy or of 4-L-[131I]iodo-phenylalanine in combination with Lomustine in participants with confirmed recurrent glioblastoma. The local investigator establishes participant’s eligibility per radiographic progression on post-contrast MRI using RANG 2.0 criteria. Follow-up [18F]FET PET image is then acquired and interpreted by the central core lab. Participants with measurable disease according to PET RANO 1.0 and TBRmax > 2.3 are registered into the study. Participants with a measurable lesion based on RANO 2.0 but not measurable based on PET RANO 1.0 are excluded.Safety is assessed based on the occurrence of adverse events reported during treatment and follow-up monitoring in Part 1. The Safety and Dosimetry Lead-In is intended to generate further safety, tolerability, and dosimetry data along with preliminary efficacy data for 4-L-[131I]iodo-phenylalanine administered concomitantly with Lomustine or as a monotherapy. 4-L-[131I]iodo-phenylalanine is administered at prescribed activity according to the BOIN design; Lomustine is prescribed as described in the BOIN (FIG. 3). Participants enter the study in Arm A, at dose level (DLA) 0. DLTs for the purpose of the BOIN de-escalation and escalation considerations include Grade > 3 thrombocytopenia and / or neutropenia monitored until 42 days after the last administered dose of 4-L-[131I]iodo-phenylalanine. Arm B opens for enrolment if according to the BOIN design the requirement for DLA -1 is fulfilled. At that time, participants are randomly assigned between Arm A, DLA -1 and Arm B, DLB 0. Arm C opens for enrolment if both Arms A and B are closed due to DLT stopping points as per BOIN.A dose-expansion cohort opens for enrolment to participants with radiographically confirmed glioblastoma to be treated with the BOIN -recommended dose of 4-L-[131I]iodo-phenylalanine in combination with Lomustine. Upon completion of the three concomitant cycles of 4-L-[131I]iodo-phenylalanine plus Lomustine, participants continue to be treated with Lomustine at the respective dose.Participants enrolled in Part 1: Safety and Dosimetry Lead-In of the study may not enrol in Part 2: Randomized Study.Initial dosing for IP AX-3 is 12 GBq 4-L-[131I]iodo-phenylalanine divided into 3 rounds of 4 GBq 4-L-[131I]iodo-phenylalanine each. The bone marrow is expected to be the dose-limiting organ. Administration of a total of 12 GBq may yield a mean bone marrow dose of about 2.12Gy. Assuming the widely accepted limit of 2 Gy, this would be expected to yield limiting bone marrow toxicity in approximately half of the subjects if given in a single dose. It is hypothesized that administering 4-L-[131I]iodo-phenylalanine in three fractions may help to reduce the overall impact on the bone marrow.The addition of Lomustine to the protocol, however, is understood to independently increase the risk of marrow toxicity, as Lomustine alone may induce cumulative myelosuppression. Thus, subjects are carefully monitored after each round of treatment to assess the potential for dose-limiting bone marrow toxicity. Dosimetry is calculated for each subject after each 4 Gy administration of 4-L-[131I]iodo-phenylalanine and blood markers of bone marrow toxicity will be closely monitored prior to moving on the next round of dosing. Total bone marrow radiation dose is monitored, and the earlier doses will permit better prediction of the total radiation dose to the marrow expected after the third administration for each subject individually. This allows de-escalation of the 4-L-[131I]iodo-phenylalanine dose as needed. This protocol yields a limiting administered dose for 4-L-[131I]iodo-phenylalanine when coadministered with Lomustine in this fractionation scheme, a value that is not currently known, while simultaneously providing the best opportunity for tumor regression.In case of a satisfactory safety profile and data review, 4-L-[131I]iodo-phenylalanine plus Lomustine are further evaluated in Part 2: Randomized Study of the proposed study.Part 2: Randomized StudyIn Part 2 and upon successful data review, participants are randomly assigned to two arms. In the investigational arm, participants are treated with 4-L-[131I]iodo-phenylalanine in combination with Lomustine as SoC chemotherapy. 4-L-[131I]Iodo-phenylalanine is administered following the established dosing regimen in Part 1: Safety and Dosimetry Lead-in. In the control arm, participants are treated with Lomustine alone.MethodologyScreeningScreening evaluations are performed < 21 days before the first dose of study drug. Patients review and sign the informed consent form (ICF) prior to initiation of any study -related procedures. Study-related procedures do not include procedures that are routinely performed.Only patients with recurrent or progressive disease identified through radiographic findings on post-contrast MRI confirmed by the local investigator, using the RANG 2.0 assessment criteria, will be consented. A positive cerebral [18F]FET PET imaging scan must be conducted within 14 days of obtaining consent, showing measurable disease (according to PET RANO 1.0 criteria) and a TBRmax > 2.3 to assure metabolic tumor progression and LAT-1expression necessary for TLXlOl-Tx transport to the tumor. Images must be submitted for central review by the Blinded Independent Central Review (BICR) within 5 business days. Positive [18F]FET PET scan will be confirmed by BICR within 5 business days of image submission.EnrolmentIn Part 1: Safety and Dosimetry Lead-In, participants are enrolled according to the BOIN schedule and the subsequent dose expansion cohort.In Part 2: Randomized Study, eligible participants are randomized to the investigational arm (4-L-[131I]iodo-phenylalanine concomitant with Lomustine) or control arm (Lomustine alone). Randomization is stratified by O6-methylguanine-DNA-methyltransferase (MGMT) methylation status (methylated, unmethylated, and unknown as determined by local investigator at initial diagnosis or at the time of re-resection, if applicable, whichever occurred last), and reresection.Throughout the study, supportive care is allowed at the discretion of the study investigator, in accordance with the best institutional practice for treatment of recurrent glioblastoma, including steroid use and other medications for symptom management. Concurrent cytotoxic chemotherapy, immunotherapy, bevacizumab, EBRT, radioligand therapy, investigational therapy, and other antineoplastic regimens are excluded from use as SoC and are not permitted during the study. The use of TTFields are excluded for Part 1 of the study and are optional for the participants in Part 2.TreatmentIn part 1: Safety and Dosimetry Lead-In, eligible participants receive the following treatment:• Arm A:Lomustine is prescribed at 90 mg / m2in 42-day cycle starting on Day 1 for all dose levels (DLA 0, -1, -2) within Arm A.4-L-[131I]iodo-phenylalanine is administered at total prescribed activity according to the DL delivered in 3 equal doses on Day 1, Day 43, and Day 85 of chemotherapy:DLA 0: 12 GBq (324 mCi) total activity in 3x 4 GBq (108 mCi) fractions DLA -1: 9 GBq (243 mCi) total activity in 3x 3 GBq (81 mCi) fractions DLA -2: 6 GBq (162 mCi) total activity in 3x 2 GBq (54 mCi) fractions.• Arm B:Lomustine is prescribed at 70 mg / m2in 42-day cycle starting on Day 1 for all dose levels (DLB 0, -1, -2) within Arm B.4-L-[131I]iodo-phenylalanine is administered at total prescribed activity according to the DL delivered in 3 equal doses on Day 1, Day 43, and Day 85 of chemotherapy:DLB 0: 12 GBq (324 mCi) total activity in 3x 4 GBq (108 mCi) fractions DLB -1: 9 GBq (243 mCi) total activity in 3x 3 GBq (81 mCi) fractions DLB -2: 6 GBq (162 mCi) total activity in 3x 2 GBq (54 mCi) fractions.• Arm C:4-L-[131I]iodo-phenylalanine monotherapy is administered at total prescribed activity according to the DL delivered in 3 equal doses on Day 1, Day 29, and Day 57:DLc 0: 12 GBq (324 mCi) total activity in 3x 4 GBq (108 mCi) fractions DLc -1: 9 GBq (243 mCi) total activity in 3x 3 GBq (81 mCi) fractions DLc -2: 6 GBq (162 mCi) total activity in 3x 2 GBq (54 mCi) fractions.In the event of treatment-emergent adverse events (TEAEs), modifications for Lomustine are permitted in accordance with the published guidelines. The subsequent cycle for Lomustine will be delayed until hematological recovery (platelet counts over 100,000 / pL and neutrophil counts over 1,500 / pL). 4-L-[131I]iodo-phenylalanine will be administered with the next scheduled Lomustine dose.In Part 2: Randomized Study, eligible participants are randomized to either the investigational or control arms and receive the following treatments:• Control Arm: Lomustine as a monotherapy• Investigational Arm: 4-L-[131I]iodo-phenylalanine concomitantly with Lomustine (or as monotherapy) at the recommended dose combination by the BOIN design and confirmed in the Part 1-Safety cohort for dose expansion.Dosimetry and Imaging Follow-UpAfter receiving the investigational medication in Part 1: Safety and Dosimetry Lead-In, the first three patients, regardless of Study Arm, undergo SPECT / CT imaging and blood sampling at pre-dose -10+5 min (blood sample only) and at post-dose timepoints at approximately +10+5 min (blood sample only), 2+1 hours (blood sample only), 4+2 hours (or longer to ensure that camera count rate is below 70,000 CPS), 24+4 hours, 48+8 hours, 96+24 hours, and 168+48 hours. SPECT / CT from the head to the abdomen is performed using a high energy collimator, attenuation correction, and triple energy window (TEW) scatter correction starting within 4 hours after the time when gamma camera total count rate falls below 70,000 counts per second (CPS).SPECT / CT imaging and blood sampling at the same timepoints are performed in these first three patients subsequently upon administration of the third dose of 4-L-[131I]iodo-phenylalanine.After the first three patients, imaging and blood sampling are performed at -10+5 min (blood sampling only), +10+5 minutes (blood sampling only) and within 4+2 hours or longer to ensure that camera count rate is below 70,000 CPS, and at 168+48 hours, A third blood sample and imaging are performed between these last two based on analysis of the data from the first three patients in order to be as close to the maximum as possible in time for both the blood radioactivity and that of all of the structures of interest. Technical details of SPECT / CT imaging are described in a separate SPECT / CT imaging Manual specific to the trial.After receiving the investigational medication in Part 2: Randomized Study, patients undergo SPECT / CT imaging on Day 1 (minimum 4-hour post-administration of 4-L-[131I]iodo-phenylalanine) to verify tumor targeting and to estimate tumor dosimetry of 4-L-[131I]iodo-phenylalanine.Patients in both Part 1: Safety and Dosimetry Lead-In and Part 2: Randomized Study are followed in parallel by conventional, SoC contrast-enhanced MRI and [18F]FET PET at intervals of 8 weeks. Disease progression is assessed according to the criteria outlined in RANG 2.0 for MRI and PET RANG 1.0 for [18F]FET PET. In cases when post-treatment change (pseudo progression) is suspected in either of the study arms, a [18F]FET PET read to the PET RANG 1.0 by central core lab will determine whether the patient event is characterized as progression of disease.Number of ParticipantsA total of approximately 18 or more participants >18 years of age may be enrolled in Part 1 of the study to include BOIN and the dose expansion safety cohort. Enrolled means a patient, or their legally acceptable representative, has agreed to participate in a clinical study following completion of the informed consent process and has been deemed eligible for participation in the study by the investigator.Study DurationScreening and determination of eligibility procedures for Part 1 and Part 2 is carried out within up to 21 days prior to the day of registration.Lomustine is continued until a cumulative dose of 1000mg / m2is reached, unacceptable toxicities, confirmed radiographic progression or death, whichever occurs first.Inclusion CriteriaAll participants must meet all the following inclusion criteria for the study.1. Previously confirmed neuropathological diagnosis of glioblastoma, IDH-wildtype according to the WHO 2021 classification.2. Patients with first progression or recurrent glioblastoma after first-line treatment with biopsy or maximal safe resection and standard radiotherapy or chemoradiotherapy having occurred at least 3 months after the end of prior radiotherapy. Prior first-line therapy may include:a. Any systemic antineoplastic treatment other than nitroureas.b. Tumor- treating fields.c. Conventionally fractionated or abbreviated (minimum 15 fractions) radiotherapy. 3. Radiographic evidence of first recurrence according to RANG 2.0 criteria.4. Increased [18F]]FET PET tracer uptake inside or in the vicinity of tumor. Specifically, amino acid-based molecular imaging using [18F]FET PET is evaluated following co- registration with MRI. The allocated physician / reader assesses whether the observed pathologically increased amino acid uptake is located within the tumor or in the vicinity. This determination serves as a guidance to confirm whether the uptake is tumor-associated. The uptake must be clearly discernible from background activity and measurable per PET RANG 1.0 criteria, with a TBRmax >2.3, as determined by central review.5. Tumor debulking at the time of radiographic resection is allowed as soon as there is radiographic evidence for residual tumor according to RANG 2.0 with increased [18F]FET PET uptake (TBRmax >2.3) and measurable disease according to PET RANO 1.0.6. Male or female >18 years of age.7. Have the capacity to understand the study and be willing to comply with all protocol requirements.8. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 and KPS>70.9. Participants on stable, not increasing dose of steroids in the previous 7 days can be included in the study.10. Adequate hematological, liver and renal function at the time of screening:a) Bone marrow:(i) Absolute neutrophil count >1.5><109 / L.(ii) Platelets >100 xl09 / L(iii) Hemoglobin >10g / dL (with no red blood cell transfusion in the previous 4 weeks).b) Liver function:(i) Total bilirubin <1.5xthe upper limit of normal (ULN).(ii) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <5xULN with participants with known liver metastases.(iii) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <3* ULN with participants with Gilbert’s Syndrome.c) Renal function:(i) Creatinine clearance >60 mL / min determined using the Cockcroft-Gault formula.11. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of investigational drug product; must not be breast-feeding; and must agree to use a highly effective method of contraception during treatment and for 6 months following last dose of investigational product.12. Male participants must agree to use condoms during sex during the treatment period and for 3 months after the last dose of the investigational drug product and must not make semen donations during treatment and for 6 months following last dose of investigational drug product. For male participants with female partners of childbearing potential, females must agree to use a highly effective method of contraception during the treatment period and for 6 months following last dose of investigational drug product.Exclusion CriteriaA participant is excluded from the study if one or more of the following criteria are met: 1. Doses to organs at risk exceeded or reached by prior radiation therapy, e.g., cumulative total dose on the optical chiasm >54 Gy for 2 Gy / fraction, a / p = 2.2. Prior treatment with brachytherapy in the brain.3. Treatment with bevacizumab within the prior 6 weeks.4. Known contraindication to imaging tracer or any product of contrast media and MRI contraindications including implanted medical devices. Unable to lie still for at least 20 min or the duration of the MRI and PET imaging or the need for use anesthesia as part of the imaging procedure.5. History or evidence of delayed-type hypersensitivity-dependent chronic infection (e.g. tuberculosis, systemic fungal or parasitic infection).6. Radiographic progression based on RANG 2.0 associated with clinical deterioration and life expectancy less than 3 months.7. Hemostaseologic conditions, precluding catheterization or invasive procedures.8. Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product.9. Known impairment of liver or kidney function or known liver or kidney disease, such as hepatitis, cirrhosis, renal failure.10. Severe chronic or active infections (including active tuberculosis, hepatitis B virus, or hepatitis C virus infection) requiring systemic therapy within 2 weeks before screening.11. Ongoing toxicity > Grade 2 NCI-CTCAE (version 5.0) from previous standard or investigational therapies.12. Administration of another investigational product within 90 days prior to screening. 13. Expected non-compliance with longer-term admission at isolated nuclear medicine ward per regional regulations.14. Inability to complete the needed investigational and standard imaging examinations due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time).15. Participants with known phenylketonuria.16. Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study investigator, would make the participant inappropriate for entry into the study., including radiotherapy or chemoradiotherapy having occurred in the last 3 months.Safety MonitoringThe safety review committee (SRC) performs assessments of safety data prior to dose escalation and will be composed, at a minimum, of one independent clinician with expertise in management of glioblastoma, an independent nuclear medicine physician or clinician with expertise in radiopharmaceutical therapy / molecular targeted therapy / nuclear oncology (ideally with experience in management of glioblastoma), the sponsor’s medical representative and the trial investigator(s). The SRC reviews and assesses all safety data with recommendations from the BOIN suite, to make decisions regarding the dose escalation.The SRC meets prior to each dose escalation and at any other timepoint as described in the SRC Plan.Statistical Analysis PlanMethodology for summary and statistical analyses of the data collected in this study is outlined here and further detailed in a statistical analysis plan (SAP). The SAP will be developed and finalized before any analyses are performed and will describe the analyses and procedures for accounting for missing, unused, and spurious data.Part 1: Safety and Dosimetry Lead-InThe BOIN design is a Bayesian dose-finding method that optimizes dose escalation and de-escalation by minimizing the chance of making incorrect dose decisions. The BOIN design for this study (Part 1) utilizes a target toxicity probability of 0.40 and eliminates doses from consideration if the probability of exceeding the target toxicity is greater than 0.95. The goal of the design is to identify the Maximum Tolerated Dose (MTD) recommended for the safety expansion cohort. The BOIN decision recommendations are summarized in FIG. 2. The steps to implement the BOIN design are as follows:1. Three participants are treated as per the rules in the table below.2. To assign a dose to the next cohort of participants, the dose escalation / de-escalation is conducted according to the rules in the table below.Number of Evaluable Participants 3 4 5 6 7 8 9 10 11 12 TreatedEscalate if # of DLT <= 0 1 1 1 2 2 2 3 3 3 Stay if# of DLT = 1 NA 2 2 3 3 3-4 4 4-5 4-5 De-escalate if # of DLT >= 2 2 3 3 4 4 5 5 6 6Eliminate if # of DLT >= 3 4 4 5 5 6 7 7 8 8 Abbreviations: DLT = dose limiting toxicity; No = number.3. The dose elimination boundaries are presented in the table below.The Elimination BoundariesThe number of evaluable participants treated at 3 4 5 6 7 8 9 10 11 12 the lowest doseStop the trial if # of DLT > 3 3 4 4 5 5 6 6 7 7 Abbreviations: DLT = dose limiting toxicity; No = number.The BOIN flow diagram is shown in FIG. 3:Screening: Written informed consent initiates outpatient or inpatient Screening period (2 weeks).Arm A: Participants enter the study in Arm A, DLA at dose level 0Arm B: Arm B is available for enrolment with participants being randomly assigned between Arm A, DLA -1 and Arm B, DLB 0Arm C: Arm C is optional if Arm A and Arm B are closed.Dose Finding Phase:The dose de-escalation phase of the study will utilize the BOIN design. After the DLT-evaluable status of each subject in a group of 3 is ascertained, one of the following decisions willbe made:• Escalate = Enrol 3 participants at a higher dose level.• If the current dose is the highest dose and the rule indicates dose escalation, new participants are treated at the highest dose. Alternatively, a new higher dose (increment not greater than 25% of current dose) may be added; then new participants are treated at the added dose. If the next dose level has been eliminated, then participants may be enrolled at the current dose level or at a new dose level 25-50% between doses.• Stay = Enrol 3 more participants at the current dose level• De-escalate = Enrol 3 participants at a lower dose level• Eliminate = Enrol 3 participants at a lower dose level and eliminate the current dose level from further consideration.The Maximum Tolerated Dose (MTD) is calculated using the isotonic regression techniques described in Yuan et al 2016. This technique estimates a toxicity probability (rounded to 2 decimal places) for each dose escalation cohort and selects as the MTD the dose level with an estimated probability closest to the protocol defined target toxicity probability of 0.40. (If two dose levels have the same estimated probability, the higher dose level is selected when the estimate is <0.40 and the lower dose level is selected when the estimate is >=0.40.)Dose Expansion PhaseThe primary objective of the expansion part of the study is to confirm the safety and tolerability of the dose chosen via BOIN. The expansion cohort enrols up to 12 participants each at the MTD or RP3D dose. The goal of this cohort is to further evaluate the safety, efficacy, dosimetry, biodistribution, pharmacokinetics (PK), and preliminary efficacy of the study. At the conclusion of part 1, the totality of data, including safety, efficacy, dosimetry, biodistribution, pharmacokinetics, and available follow-up data, will be assessed by an SRC consisting of independent scientists and clinicians and decision regarding the implementation of the BOIN steps and the opening of Arms B and C will be made, including the need for dose adjustment. The SRC will also make recommendations to the sponsor about potentially halting the study due to safety issues.Planned Primary Endpoint Analysis ( Part 1 )The primary analysis for Part 1 takes place after all participants have finished protocol treatment. At the conclusion of Part 1, the totality of data, including safety, efficacy, dosimetry, biodistribution, pharmacokinetics, and available follow-up data, is assessed by an SRC.SafetyFor each treatment arm, the following analyses will be performed. Descriptive statistics will be provided for safety endpoints per study part and per dose level / arm. AEs will be coded using MedDRA and summarized by system organ class and preferred term. Only treatment-emergent AEs will be summarized. A summary of the number and percentage of participants with the following AEs during the study will be displayed:• All TEAEs.• All AESI.• All drug related AEs (AEs with a possible, probable or definite relationship to study drug).• AEs by severity.• AEs by relationship to study drug.• SAEs.Safety and tolerability will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events will be assessed, and the grade and relatedness will be recorded. These assessments will take place throughout the ...

Claims

CLAIMS1. A method of treating a glioma comprising administering a therapeutically effective amount of a compound of Formula I:whereinX is selected from the group consisting of -O-, -N(H)-, -N[(C3-C6)cycloalkyl]-, and -N[(Ci-C6)alkyl]-;R1and R2are each independently selected from the group consisting of -H, -PG, -CFhAr, -(Ci-C4)alkyl, and -(C3-C7)cycloalkyl, or X and R1together form a (C3-Cs)heterocycle;R3is selected from the group consisting of -I, [123]I, [124]I, [125]I, and [131]I;R4is selected from the group consisting of -H, -F, or [18]F;R5is selected from the group consisting of -PG, -(Ci-C6)alkyl, and -(C3-C6)cycloalkyl; R6and R7are each independently selected from the group consisting of -H, -PG, -CH2 Ar, -(Ci-C4)alkyl, and -(C3-C6)cycloalkyl, or R6and R7together form a (C3-C5)heterocycle;wherein, if present, each PG is independently a protecting group;m is 0, 1, 2, or 3;n is 0, 1, or 2;or a pharmaceutically acceptable salt or stereoisomer thereof;in combination with a nitrosourea chemotherapy, to a patient in need thereof.

2. The method of claim 1, wherein the compound of Formula I is 4-L-[131I]iodo-phenylalanine.

3. A method of treating a glioma comprising administering a therapeutically effective amount of 4-L-[131I]iodo-phenylalanine in combination with a nitrosourea chemotherapy to a patient in need thereof.

4. The method of any one of claims 1 to 3, wherein the glioma is a glioblastoma, optionally wherein the glioblastoma is a high-grade glioma.

5. The method of any one of claims 1 to 4, wherein the glioma is a recurrent glioblastoma, optionally wherein the recurrent glioblastoma is a recurrent high-grade glioma.

6. The method of any one of claims 2 to 5, wherein the 4-L-[131I]iodo-phenylalanine is administered in an amount of between about 2 GBq and about 18 GBq.

7. The method of any one of claims 2 to 6, wherein the 4-L-[131I]iodo-phenylalanine is administered as more than one dose.

8. The method of any one of claims 2 to 7, wherein the 4-L-[131I]iodo-phenylalanine is administered as two or more, substantially equal doses of 4-L-[131I]iodo-phenylalanine.

9. The method of any one of claims 2 to 8, wherein the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of 4-L-[131I]iodo-phenylalanine.

10. The method of any one of claims 2 to 9, wherein the 4-L-[131I]iodo-phenylalanine is administered as three, substantially equal doses of between about 2 GBq and about 7 GBq, per dose.

11. The method of any one of claims 2 to 10, wherein the 4-L-[131I]iodo-phenylalanine is administered intravenously; optionally wherein the 4-L-[131I]iodo-phenylalanine is administered intravenously via an automated infusion system.

12. The method of any one of claims 2 to 11, wherein the 4-L-[131I]iodo-phenylalanine is formulated in a buffered solution for injection; optionally wherein the 4-L-[131I]iodo-phenylalanine is formulated for a single intravenous use; optionally wherein the 4-L-[131I]iodo-phenylalanine is formulated in an amount of about 8 mg to about 12 mg of 4-L-[131I]iodo-phenylalanine per about 25 mL of the buffered solution.

13. The method of any one of claims 2 to 12, wherein the 4-L-[131I]iodo-phenylalanine is administered as more than one dose at a regular or an irregular time interval of about two weeks, about three weeks, about four weeks, about five weeks, about six weeks, about seven weeks, about eight weeks, about nine weeks, or about ten weeks.

14. The method of any one of claims 1 to 13, wherein the nitrosourea is administered in an amount of 1 mg / m2to 500 mg / m2, per day.

15. The method of any one of claims 1 to 14, wherein the nitrosourea is administered at the same time interval as the 4-L-[131I]iodo-phenylalanine.

16. The method of any one of claims 2 to 15, wherein the nitrosourea is administered on the same day or days as the 4-L-[131I]iodo-phenylalanine.

17. The method of any one of claims 2 to 16, wherein the nitrosourea is administered for at least the same duration of time as the 4-L-[131I]iodo-phenylalanine.

18. The method of any one of claims 1 to 17, wherein the nitrosourea is selected from the group consisting of Lomustine, Carmustine, Fotemustine, and a combination thereof.

19. The method of any one of claims 1 to 18, wherein the nitrosourea is Lomustine.

20. The method of claim 18 or claim 19, wherein the Lomustine is administered in an amount of between about 60 mg / m2and about 110 mg / m2, per day.

21. The method of any one of claims 1 to 20, wherein the method further comprises the step of administering a nitrosourea during a maintenance period.

22. The method of claim 21, wherein the nitrosourea is administered during a maintenance period in an amount of between about 1 mg / m2and about 500 mg / m2, per day.

23. The method of any one of claims 1 to 22, further comprising administration of external beam radiotherapy.

24. The method of claim 23 , wherein the external beam radiation is administered in an amount of about 20 Gray to about 70 Gray, optionally about 30 Gray to about 60 Gray.

25. The method of claim 23 or claim 24, wherein the external beam radiation is administered in one or more fractions, optionally in about 10, about 20, or about 30 fractions, optionally about 20 to about 30 fractions.

26. The method of any one of claims 23 to 25, wherein the external beam radiation is administered in fractions of about 2 Gy, optionally wherein the external beam radiation is administered in about 20 to about 30 fractions of about 2 Gy.

27. The method of any one of claims 23 to 26, wherein the external beam radiation is administered for a duration of about six weeks.

28. The method of any one of claims 1 to 22, further comprising administration of Temozolomide chemotherapy.

29. The method of claim 28, wherein the Temozolomide is administered in an amount of between about 75 mg / m2and about 200 mg / m2, per day.

30. The method of claim 28 or claim 29, wherein the Temozolomide is administered in an amount of about 75 mg / m2, per day.

31. The method of any one of claims 28 to 30, wherein the Temozolomide is administered in an amount of about 75 mg / m2daily for a duration of about 6 weeks from commencement of treatment.

32. The method of any one of claims 1 to 22, further comprising administration of external beam radiotherapy and Temozolomide chemotherapy.

33. The method of any one of claims 1 to 32, wherein a reduction in one or more adverse events is observed as a result of the method in comparison to administration of a nitrosourea chemotherapy alone.

34. The method of any one of claims 1 to 33, wherein the method provides for an increase in the progression free survival of the patient in comparison to administration of a nitrosourea chemotherapy alone.

35. The method of claim 34, wherein the progression free survival is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of a nitrosourea chemotherapy alone.

36. The method of any one of claims 1 to 35, wherein the method provides for an increase in overall survival of the patient in comparison to administration of a nitrosourea chemotherapy alone.

37. The method of claim 36, wherein the overall survival is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, in comparison to administration of a nitrosourea chemotherapy alone.